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Parkinson’s disease (PD) is an incurable, chronically progressive disease leading to 
premature invalidity and death. Early diagnosis of PD is expected to dramatically improve 
the outcome of therapies under current development, therefore we interrogated a human 
neuronal cell-based model of PD for the earliest detectable functional alterations. Neurons 
derived from induced pluripotent stem cells (iPSC) representing healthy individuals and 
LRRK2 associated PD patients formed complex networks that showed evident signs of 
functional maturation over time. However, PD neuronal networks developed abnormal 
hypersynchrony, in contrast with healthy or gene-edited isogenic PD networks.  
By combining functional calcium imaging, biophysical modeling, dopaminergic neuron 
(DAn)-lineage tracing and gene expression profile analysis, we found that a decrease in 
DAn neurite length triggered overall functional alterations in the PD networks. Thus, our 
results identify early alterations in PD neuronal function that predate the onset of neuron 
degeneration and highlight the extraordinary window of opportunity that iPSC-based 
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1. PARKINSON DISEASE (200 years from the discovery of the disease) 
 
1.1  Introduction and clinical features 
Two centuries ago, James Parkinson described Parkinson’s Disease (PD) as a neurological 
disorder for the first time in his monograph entitled An Essay on the Shaking Palsy1. In the 
last 200 years this disease has been extensively studied and today we define PD as a 
progressive neurodegenerative movement disorder, clinically characterized by distinctive 
motor symptoms including bradikinesia, resting tremor, rigidity and impaired postural reflex2. 
The disease’s progression is characterized by asymmetric onset of the signs and symptoms 
and a good response to levodopa treatment. However, PD affects many areas of the brain, 
also causing non-motor symptoms including anosmia, autonomic disturbance, sleep 
disorders, gastrointestinal dysfunctions, speech/swallowing problems and cognitive decline 
that may progress to dementia (80% of cases over 20 years of the disease)3–7. 
 
1.2 Neuropathological features of PD 
PD’s known hallmarks are the preferential loss of striatal projecting dopaminergic neurons 
(A9) of the sustantia nigra pars compacta (SNpc) and the presence of ubiquitin-positive 
inclusions in surviving neurons, mainly composed of the neuronal protein alpha-synuclein 
(α-syn); known as Lewy Bodies (LB)8,9. 
A9 ventral midbrain dopaminergic neurons display strong neuromelanin pigmentation10. 
They project through the striatum first in the putamen and then in the caudatum, and their 
main role is to regulate the release of dopamine in the striatum to initiate the execution of 
movement. During PD pathogenesis the loss of dopaminergic neurons is observable by a 
SNpc neuromelanin depigmentation and results in a progressive dysfunctionality in the 
motor circuitry of the basal ganglia that leads to motor impairments11. Importantly, when the 
symptoms display, almost 50% of the dopaminergic neurons (DAn) have already been lost. 
Reduced levels of dopamine correlates with the severity of the symptoms12. Lewy bodies 
are typical not only in the SNpc but also in other areas of the central nervous system (CNS). 
They have been characterized as an abnormal, post-translationally modified and aggregated 




1.3 Prevalence and etiology 
 
PD is the second most prevalent movement disorder and chronic neurodegenerative 
disease, after Alzheimer’s disease (AD), affecting between seven to ten million people 
worldwide 14. The causes of the neurodegeneration triggering PD are still unknown, 
however, 15% of patients with PD have a familial history, suggesting a genetic factor. 
Several mutations in different genes lead to familial PD such as LRRK2, PARK7, PINK1, 
SNCA, or PARKIN genes15,16,25–27,17–24. Other genetic variants, such as mutations in the GBA 
and UCHL1 genes are known to increase the risk of PD28, and still others are being 
investigated. 
PD’s etiology typically involves an interaction between genetic predispositions and other 
environmental factors: infectious (influenza, whooping cough), toxic (pesticides, solvents) 
and other exposure (rural residence, drinking well water) have been identified as possible 
risk factors.  
The most influential risk factor in PD is ageing. It’s well known and described that 
physiological ageing causes changes in gene expression, immune function, mitochondrial 
integrity, and metabolic efficiency29,30. Interestingly, DA neurons seems to be more 
vulnerable to this age associated degeneration process compared to other types of 
neuron11.  
Gender is another PD risk factor.  The female to male ratio for PD has been demonstrated 
to be 1:1.5/2 with women developing the disease a mean of 2.2 years later compared to 
men31. Different epidemiologic studies suggest that the differences in the onset of the 
disease between women and men are due to the fact that women have a higher initial striatal 
dopamine level compared to men, this could delay the onset of the motor symptoms; and 
that estrogen seems to have a mild neuroprotective role32. Cigarette smoking33–35, coffee 
and tea drinking and a high level of physical activity in midlife34,36 are also associated with 
lower risk of developing PD.  
  
1.3.1 Environmental causes 
Environmental toxins play a role in PD neurodegeneration, however the current consensus 
is that they do not induce the disease: they are always associated with genetic 
predispositions. Their influence is nonetheless interesting mainly because the role of 
environmental toxins in the pathogenesis of PD is still not fully clarified37. 
Several viruses have also been proposed as playing a role in the onset of the disease, with 
evidence showing that patients contracting influenza in the 1918 epidemic display cases of 
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lethargic encephalitis, which exhibited Parkinsonism. These patients reacted well to anti-PD 
medication for a period of time38, but did not exhibit characteristic Lewy pathology (LP) 
during autopsy. A hypothesis offers the theory that the influenza virus infection was not a 
direct cause of PD, but was the “first hit” that opened the way for a second stressor in a 
“dual-hit” theory 39,40. 
Another potential environmental trigger of PD can be exposure to pesticides like rotenone. 
Infusion of rotenone into the substantia nigra of mice or rats has been found to create PD-
like characteristics. The dosage and method of administration of the rotenone change the 
outcome: a systemic administration causes a multisystemic degeneration unlike the 
degeneration seen in PD41, and high doses are selectively damaging to the striatum and 
globus pallidus, but spare the substantia nigra42,  a chronic, per oral exposure to rotenone 
(more likely to mimic the natural exposure to this pesticide) was shown to give rise to a PD-
like pathology. This pathology originates in the enteric nervous system before spreading to 
the substantia nigra, causing a loss of dopaminergic neurons and PD-like characteristics43. 
Interestingly, when the vagal nerve was resected in a later study, the disease’s progression 
to the brain was interrupted44 suggesting a prion-like behavior of this disease. 
The case for rotenone as an environmental factor is supported by data showing that living 
in rural areas (with higher exposure to pesticides) correlates with increased risk of 
developing PD compared to living in urban areas45. This has been disputed by other studies 
that found no significant difference in the prevalence between urban and rural areas46. 
 
1.3.2 Autosomal dominant monogenic forms of PD 
Several autosomal dominant monogenic mutations are known to be the cause of PD. The 
first gene discovered to be associated with PD was the SNCA gene (α-syn). The 1997 paper 
Polymeropoulos et al. used a traditional linkage approach on a large Italian family to track 
the underlying genetic lesion to an area located in the long arm of human chromosome 447. 
This discovery corroborated the study by Spillantini et al (1997)8 that describes how α-
synuclein protein is the major component of the LB, the pathological hallmark of PD48,49, 
proving a familial form of PD. 
A duplication or triplication of the SNCA locus is a frequent cause of PD providing a 
pathogenic overexpression of wild type -synuclein; duplication in the gene is often 
indistinguishable from idiopathic PD while the triplications display an early onset fulminant 
disease26,50–52. A single copy of the SNCA gene with any of five different missense mutations 
is also linked to PD: A53T, A30P, E46K, H50Q and G51D53–55. 
Another known monogenic cause of PD is mutation in the VPS35 gene. The mutation D620N 
was described by two groups in 2011 and accounts for ≈1% of all familial cases of PD, 
though the symptoms are similar to idiopathic PD. Furthermore, several non-synonymous 
base exchanges have been identified, but their pathogenicity remains unknown56,57.  
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R1205H and A502V mutations in the gene eukaryotic translation initiation factor 4 gamma 
(EIF4G1)58,59, and Thr6Ile and Arg145Gln in the gene CHCHD2 and its twin gene CHCHD10 
are also associated with autosomal dominant PD. Interestingly, mutations in 
CHCHD2/CHCHD10 seem to be connected with a specific PD phenotype such as 
mitochondrial dysfunction60–62. 
The most important autosomal dominant mutation in this study is the LRRK2 G2019S, 
discovered on chromosome 12, by Funayma at al. in 2002 and directly correlated with 
familial PD in 200424,25,63. The LRRK2’s mutations are estimated to be present in 
approximately 4% of all PD cases and the most frequent of these mutations is the one that 
we are currently analyzing, G2019S64–67, this presents in 1% of sporadic cases and 3%-6% 
of familial PD cases. Clinically PD caused by LRRK2 mutations is indistinguishable from the 
pathology seen in sporadic cases of PD; the first symptoms appear in the sixth decade and 
dystonia is typical of the disease progression. Nevertheless, most LRRK2 cases described 
until now demonstrate common features like LB in the brainstem and loss of neurons in the 
SNpc, although a minority of cases exhibit neurofibrillary tangle pathology, glial cytoplasmic 
inclusions reminiscent of multiple system atrophy, or neuronal nigral loss without LB68.  
 
1.3.3 Autosomal recessive monogenic forms of PD 
Autosomal recessive PD is often correlated with early onset and slow progression of the 
symptoms. Mutations in the parkin gene are known to be the most common cause of 
autosomal recessive early onset parkinsonism and also to be the cause of autosomal –
recessive juvenile parkinsonism22,69. The connections between this gene and PD are 
complex; 79 mutations in parkin have been reported in familial and sporadic PD patients, 
but interestingly, PD is associated with heterozygous parkin mutations with an apparently 
dominant pattern of transmission, implying that carriers of a single parkin mutation might be 
at risk of developing PD70–72. The heterogeneity of the symptoms makes it difficult to draw 
clinical connections between a given phenotype and a specific mutation. 
Mutations in DJ-1 and PINK1 are also connected with autosomal recessive PD with clinical 
features similar to the ones observed in patients with parkin mutations20,73–75. Mutations in 
RAB39B gene were more recently discovered to cause X-linked and early onset PD76–78. 
Further, in 2012 a connection was described between mutations in the DNAJC6 gene and 
childhood Parkinsonism with early onset slow progression PD and good response to 
dopaminergic therapy79–81.  
 
1.3.4 Genetic risk factors and susceptibility 
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The gene most commonly associated with higher susceptibility to develop PD is GBA, the 
lysosomal enzyme glucocerebrosidase (GCase), which causes the lysosomal storage 
disorder, Gaucher disease (GD). There are 3 known types of GBA related diseases with a 
wide range of symptoms. Type 2 and 3 are generally associated with neurological 
phenotypes but type 1 has often been connected with PD. Heterozygous mutations in GBA 
are now known to be one of the most common genetic risk factors for Parkinson's disease 
and dementia with Lewy bodies (DLB) 82–84. 
Other PD susceptibility factors involve mutations in MAPT85, MC1R86, ADH1C87 and other 
genes (view Table 2). In sporadic PD forms, the involvement of environmental factors in 
initiation and progression of the disease suggests that epigenetics plays an important role88. 
An example of an epigenetic mechanism in PD is the modification of the α-syn gene (SNCA). 
Matsumoto et al.89 found that CpGs in SNCA were hyper-methylated in controls, but not 
methylated in PD patients, suggesting that lack of methylation was an epigenetic risk factor 
for PD that is related to the pathogenesis of α-syn90.  
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Table 1: PD related genetic risk factors 
Inheritance 
pattern 
Locus Mutation site Involved protein 
Autosomal 
dominant 
PARK1 SNCA -syn 
PARK3 SPR Sepiapterin reductase in BH4 
pathway 
PARK4 Triplication of 
SNCA 
-syn 
PARK5 UCHL1 Ubiquitin C-terminal hydrolase 
PARK8 LRRK2 Leucine-reach repeat kinase 2 
PARK11 GIGYF2 GRB10-interacting GYF protein 2 





PARK17 VPS35 Vacuolar protein sorting 35 
PARK18 EIF4G1 Eukaryotic translation initiation 
factor 4 gamma 
1 
PARK21 DNAJC13 DNAJ-domain-bearing protein 
Autosomal 
recessive 
PARK2/PARKN Parkin Ubiquitin-protein ligase 
PARK6 PINK1 PTEN-induced putative kinase 1 
PARK7 DJ1 Oncogene DJ1 
PARK9 ATP13A2 Lysosomal type 5 P-type atpase 
PARK14 PLA2G6 Phospholipase A2 
PARK15 FBXO7 F-BOX only protein 
PARK19 DNAJC6 Putative tyrosine-protein 
phosphatase auxilin 
PARK20 SYNJ1 Synaptojanin-1 




Table 2: PD related susceptibility factors 
 Involved gene Putative function Phenotype 
Susceptibilit
y factors 























Imamura et al., 2003 
ATXN2 Ataxin-2 Spinocerebellar ataxia 2 
ATXN3 Ataxin-3 Machado-Joseph disease 
TBP TATA box-
binding protein 
Spinocerebellar ataxia 17 
ATXN8OS Ataxin-8 opposite 
strand 
Spinocerebellar ataxia 8 










1.4 Molecular mechanisms involved in PD 
 
PD is described as a systemic pathology. Neurons, especially DA, are the most involved 
and present signs typical of the disease but other brain cells are also affected, such as 
astrocytes and microglial cells, and alterations are observed in other organs including the 
gut, the immune system and the peripheral nerves. 
All these different types of cells have specific PD related cellular features in common, shown 
in the Figure 1, that together explain the molecular bases of the disease.  
 
 
Fig. 1. Different molecular mechanisms contribute to the onset of PD. Adapted from S. Przedborki (2017). 
DOI: 10.1038/nrn.2017.2591, this diagram shows the main known mechanisms and their interactions. Critical 
to PD pathology are the quality-control mechanism regulating production, folding and degradation of proteins 
and organelles such as -syn and mitochondria. Misfolded proteins result from gene mutation or post-
translational modification induced by ROS. These misfolded proteins can alter the ubiquitine-proteasome and 
lysosomal degradation pathways. They may also to be able to travel from cell to cell propagating the disease. 
ROS itself can cause broad cellular damage and directly contribute to neurodegeneration. ROS can be 
generated by the oxidation of dopamine (the major neurotransmitter used by dopaminergic neurons), by 
environmental toxins like 6-OHDA and by mitochondrial repair defects. Mutations in PINK1 and Parkin are 
also connected with mitochondrial impairment and PD. Similar effects are caused by the environmental toxins 
Rotenone and MPTP. Defective mitochondrial respiration is also responsible for a decrease in the ATP 
production that causes oxidative stress and accumulation of Ca2+ which is toxic for the cells and leads to an 
energy crisis. All these mechanisms are prevalent in DA neurons but also affect glial cells which are activated 
by the degeneration process and adopt a pro-inflammatory phenotype. This phenotype enhances the 




A key component of PD pathogenesis is the intracellular accumulation of misfolded proteins, 
in particular -syn8. The misfolded proteins are collected in Lewy bodies, hyaline inclusions 
in cell bodies and neurites across the brain9. It has been demonstrated both genetically and 
pathologically that the autophagic clearance system that maintains proteostasis is impaired 
in PD; misfolded -synuclein proteins block their own degradation by autophagic impairment 
and consequently prevent the degradation of other proteins causing the formation of Lewy 
bodies92–94. Mutated, misfolded or overexpressed α-synuclein is involved in a number of 
pathways associated with degeneration of SNpc DA neurons including impairment in the 
synaptic function95,96, mitochondria respiration and turnover97,98, microtubule assembly and 
axonal transportation99 and endoplasmic reticulum (ER) stress100. Recent studies101,102 
propose a prion-like hypothesis: it has been demonstrated that α-synuclein aggregates 
spread between cells and that this contributes to the PD disease process. Interestingly these 
proteins spread not just in the dopaminergic neurons but also in other neurons and organs 
like peripheral nerves and the enteric nervous system103. The spread of a prion-like 
conformed -synuclein might play an important role in the progressive worsening of 
symptoms and the gradual involvement of additional brain and autonomic functions as the 
disease advances101. 
 
1.4.2 Mitochondrial dysfunction 
 
Both familial and sporadic PD often display impairments in mitochondrial homeostasis104,105. 
PINK1 and Parkin play an important role in the control of mitochondrial turnover and 
protection against oxidative stress. The mutations in these genes are implicated in reducing 
mitochondrial calcium capacity and reactive oxygen species (ROS) induction. These 
processes increase the vulnerability of the cells106. Recent findings also show that 
mitochondrial transport, necessary for energy supply especially in long axon DA neurons, 
may be affected in PD. Studies correlate this impairment with mutations in Parkin, α-syn, or 
LRRK2 because they modulate microtubule stability107, or by formation of α-syn 
aggregates108. 
 
1.4.3 Dopamine impairment 
 
It is long established that in PD patients there is a substantial dopamine deficit both in the 
striatum and in the SNpc. 2 studies described this characteristic in the 1960s: Sano, I. 
Biochemistry of the extrapyramidal system. Shinkei Kennkyu No Shinpo 5, 42–48 (in 
Japanese) (1960)109; Ehringer, H. & Hornykiewicz, O. Verteilung von noradrenalin und 
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dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des 
extrapyramidalen systems. Klin. Wochenschr. 38, 1236–1239 (in German) (1960)110. 
Dopamine deficit causes motor symptoms in PD due to the disruption of the nigrostriatal 
pathway in the striatum, which is a crucial part of the basal ganglia circuitry controlling 
movement111,112. The administration of L-DOPA (dopamine precursor) is currently the 
most used symptomatic treatment to efficiently reduce the motor symptoms113. 
 
1.4.4 Axonal damage  
 
Neurodegeneration and the loss of dopaminergic neurons are well established causes of 
PD motor symptoms. New studies focus on the preclinical stage of the disease to understand 
the early stages of the neurodegeneration, looking for new therapeutic targets and early 
diagnosis techniques.  
A key player in the early stage of the disease seems to be dopaminergic axonal 
degeneration associated with -syn accumulation114. Over the last decade, different groups 
have monitored PD patients using imaging techniques including DAT scan and PET115,116, 
with tracers applied to measure the activity of vesicular monoamine transporter type 2 
(VMAT2), aromatic l-amino-acid decarboxylase (AADC) or the dopamine transporter (DAT), 
all of which are expressed in or on DA axonal terminals (as well as in DA neuronal soma) 
and can be used as proxy measures of DA axonal length and integrity of the soma. These 
studies are in accord that there is a more profound loss of DA striatal axonal terminals at the 
early stages of PD. In particular, they highlight how dopaminergic fibers in the dorsal 
striatum, which are known to be part of the nigrostriatal pathway and connected with motor 
function in PD, are only moderately affected at 1 year post the PD diagnosis, more severely 
affected at 3 years and virtually absent by years 4–5 and thereafter. Though the data was 
variable, the decrease in the number of tyrosine hydroxylase dopaminergic neurons (TH) 
positive neurons in the SNpc was robust even at the earlier time points with a relatively minor 
loss over time and with a residual population of TH positive neurons even decades after 
diagnosis117.  
Induced pluripotent stem cell (iPSC) models of PD connect the axonal degeneration 
phenotype with -syn accumulation allowing new insights on the timing of the -syn 
accumulation and on its correlation with the other pathological phenotypes.  
Oliveira and colleagues have demonstrated that iPSC derived neurons from PD patients 
with SNCA triplication have lower neuronal connectivity and a deficit in spine formation 
compared to controls118. These phenotypes have been confirmed with other iPSC neurons 
derived from PD patients with SNCA triplication and LRRK2 (G2019S) mutation18,119,120. 
Another study with iPSC-derived DA neurons carrying SNCA triplication or the LRRK2 
(G2019S) mutation describes how these neurons display abnormalities in neurite length, 
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axonal degeneration, blebbing and fragmentation121. In an important study, Kouroupi et al. 
reported significantly increased α-syn load in iPSC-derived DA neurons from two patients 
with early-onset PD with the p.A53T SNCA mutation, compared to controls. These neurons 
contain the pathological form of -syn and exhibit protein aggregation, developed α-syn-
positive varicosities, neurite swelling and fragmentation. Interestingly, dopaminergic 
neurons derived from the p.A53T SNCA PD iPSC show impaired ability to form synapses. 
All of this evidence connects to -syn pathology, synaptic and axonal degeneration using 




To date, there is no cure for Parkinson’s disease. The treatments on the market are 
symptomatic, helping patients to control the motor/non-motor symptoms. These treatments 
improve the quality of life, and, ameliorate some functional capability, but they do not cure 
the disease and are only have temporary effects on the non-motor symptoms. The DA 
replacement drug, Levodopa (L-DOPA), remains the most effective treatment for PD motor 
symptoms and its efficacy and tolerability is firmly established after more than 30 years of 
use in clinical practice123,124. This drug only alleviates the symptoms of PD for a period of 
approximately 5 years. 
L-DOPA is a precursor of dopamine that can cross the cross blood-brain barrier, which 
dopamine itself cannot125. Once in the brain, L-DOPA is processed and converted into 
dopamine by the enzyme L-amino acid decarboxylase restoring the normal level of this 
neurotransmitter (which is typically low or absent). L-DOPA is normally administered in 
combination with Monoamine Oxidase B enzyme (MAO-B) inhibitors, Catechol-O-
Methyltransferase (COMT) inhibitors and dopamine agonists (Benserazide, Carbidopa) in 
order to prevent formation of dopamine in the peripheral tissues, which can result in adverse 
effects such as nausea and vomiting. L-DOPA treatment improves motor symptoms and 
patients’ quality of life but, after five years of treatment, it causes side effects which can be 
worse than the actual symptoms of PD113.  
New experimental therapies are in pre-clinical and clinical trial, using non-dopaminergic 
systems treatments for the symptoms of PD such as adenosine, glutamatergic, adrenergic, 
serotoninergic, histaminic, and iron chelator pathways. These treatments, administered in 
conjunction with L-DOPA, represent potential therapeutic targets for motor symptoms but 
their efficacy is still to be proven126. 
 
 
2. Ventral midbrain dopaminergic neurons physiology and pathology during PD 
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Ventral midbrain dopaminergic (DA) neurons selectively degenerate during the progression 
of PD, making them the main target of this research. 
 
2.1 Anatomy and neurodevelopment 
 
DA neurons are located in the SNpc (A9 group), ventral tegmental area (VTA, A10 group) 
and the retrorubral field (RRF, A8 group). These neurons are anatomically very close and 
share developmental profiles and origin. There are several neural circuits established by DA 
neurons: the nigrostriatal pathway that connects SNpc with the striatum, the mesolimbic 
pathway that connects DA neurons in VTA with the nucleus accumbens (NAc) and the limbic 
systems, and the mesocortical pathway that connect VTA neurons with the prefrontal cortex 
(Figure 2). Taken together we can confirm that dopaminergic neurons play a key role in 






Fig. 2.  A schematic diagram illustrating DA neuron clusters in the Substantia nigra (A9) and VTA (A10) in the 
adult human brain. Indicated with red arrows are the dopaminergic pathways that start from the SNpc and 
end in the Striatum. Indicated with green arrows are the pathways that start in the VTA and end in the nucleus 
acumbens, frontal cortex and hippocampus. The dopamine pathways are physiologically involved in many 
functions such as reward and motivation, pleasure and euphoria, fine tuning in motor functions, compulsion 
and preservation. Adapted from E. Scarr et al. (2013). DOI: 10.3389/fncel.2013.00055127. 
The development of the midbrain starts during the definition of the neural tube structure 
when two signaling centers are forming: the isthmic organizer (IsO) that defines the 
midbrain-hindbrain boundary (MHB)128–130, and the floor plate (FP), which controls ventral 
identities131. These two areas release transcription factors and morphogens that induce the 
regional identity of the ventral midbrain (vm) and the specification and proliferation of 
midbrain dopaminergic progenitors. 
The temporal and spatial inhibition/induction of Wingless/Integrated signaling pathway 
(Wnt1) and Sonic Hedgehog signaling pathway (SHH) are crucial for the regulation of ventral 
midbrain patterning and ventral midbrain dopaminergic neurons have been mapped from 
progenitors expressing Shh or Wnt1132–134. These inputs are integrated in the vm precursors 
by Forkhead Box Protein A1 and A2 (FOXA1/2) and Orthodentical Homeobox 2 (OTX2)135 
expression that regulates two lim homeobox transcription factors, Lmx1a and Lmx1b. Lmx1b 
is necessary for the differentiation of mDA progenitors136. Lmx1a is required for the 
specification of mDA neurons in the brain137,138 and, via muscle segment homeobox homolog 
1 (Msx1), to suppress the emergence of basal plate fate139. We can conclude that the 
concerted action of the SHH-FOXA2 and the OTX2-Wnt1-Lmx1a/Msx1 networks is essential 
not only for the specification of the ventral midbrain floor plate but also for the suppression 
of alternative neural fates. 
After neurogenesis, post mitotic midbrain dopaminergic neurons migrate to reach their final 
location in the SNpc, VTA and RrF140,141. This process is regulated by some early factors 
described above such as Otx2, Lmx1a/b, Foxa1/2 and the homeobox genes En1/2 
(engrailed 1/2), which remain expressed in post mitotic DA cells; these factors also regulate 
the activity of late transcription factors such as nuclear receptor related 1 protein (Nurr1) that 
control the progressive acquisition of appropriate neurotrophic factor and DA 
neurotransmitter phenotype.  
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Fig 3. Genetic networks controlling the development of the midbrain-hindbrain and mDA neurons in the mouse 
brain from E Arenas et al. (2015) DOI: 10.1242/dev.097394142 
 
 
2.2 Main roles and connections 
 
In physiological conditions the dopaminergic neurons present in the SNpc activate the 
neurons that express D1 dopamine receptor in the striatum through a direct pathway and 
inhibit the D2-expressing striatal projecting neurons of the indirect pathway91. The direct 
pathway is activated by the cortex and the SNpc, this direct pathway inhibits the globus 
pallidus internal segment (GPi)–substantia nigra pars reticulata (SNpr). When the indirect 
pathway is activated by the cortex, and in a minor way inhibited by the SNpc, it inhibits 
the globus pallidus external segment (GPe), this in turn inhibits the subthalamic nucleus 
(STN) and the GPi–SNpr. Put together, the direct and indirect pathways on the GPi–SNpr 
result in a net decrease in inhibition in the thalamus. The thalamus is responsible for 
activating the motor cortex itself, so an increase in activity in the SNpc promotes motor 
activity. In pathological conditions like PD, there is a clear degeneration of the SNpc that 
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causes a pathological dysregulation of the fine balance between the activation of the 
direct pathway and the inhibition of the indirect pathway. Due to this mechanism there is 
an increase in the activation caused by STN and a decrease in the GPe-mediated 
inhibition of the GPi–SNpr, which, in turn, will exert a much stronger inhibition of the 
thalamus, causing lower activation of the motor cortex. In conclusion, the loss of the 
inputs of the SNpc direct to the striatum leads to a decrease and impairment in motor 
activity143.  
 
2.3 Hypothesis of neurodegeneration 
 
The first steps of neurodegeneration and how the pathogenic mechanisms previously 
described lead to PD are still not fully understood. The literature attributes 
neurodegeneration in PD to different hypotheses that collect all the cellular mechanisms 
described above which lead to the selective loss of dopaminergic neurons. The 2 leading 
hypotheses are: 
a. Aggregation of proteins  





2.3.1 Aggregation of proteins hypothesis 
 
This hypothesis is supported by the evidence of Lewy pathology (LP) - proteceous inclusions 
that are rich in fibrillary forms of -syn, in the SNpc of PD patients9. It has been demonstrated 
that Lewy bodies, the main cause of LP, are present in different stages of the disease in 
other areas of the brain like the olfactory bulb and the dorsal motor nucleus of vagus (DMV) 
in the caudal medulla before propagating to the SNpc through synaptically coupled 
networks103,144.  
Recent studies suggest a prion-like behavior of the oligomeric misfolded -syn. This event 
may start outside the CNS, in the gut, with the misfolded proteins traveling along the vagus 
nerve to reach the CNS. Once in the brain, they spread to different areas and are responsible 
for the proteceous inclusions formation and the neurodegeneration of the SNpc DA 
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neurons101. Even though the connection between -syn and PD is clear, the molecular 
mechanisms that connect -syn pathology with cell death and PD symptoms remains 
uncertain145,146.  
It is still debated why SNpc DA neurons should be particularly vulnerable to propagated -
syn aggregates and Lewy bodies accumulation given the fact that in low chronic doses these 
misfolded proteins do not appear to be particularly toxic. In many parts of the brain 
(particularly the brainstem), Lewy bodies can be present for decades without causing any 
obvious degeneration or neuronal death147–149. Lewy bodies do not spread in the closest 
neighbor of the SNpc, only in specific areas like DMV, intermediate reticular zone and raphe 
magnus. There are sporadic PD patients with very little Lewy bodies accumulation and 
cases in which SNpc DA neurons appear to be lost before Lewy bodies are present in the 
SNpc. Lewy bodies accumulation is not present in some familial cases despite loss of SNpc 
DA neurons11,150–152. 
Misfolded proteins are toxic for all neurons as a result of many different mechanisms such 
as: interference with intracellular neurological traffic pathways, sequestration of key proteins 
for cell survival, inducing cell cycle arrest and indirectly affecting the process responsible for 
recognizing and destroying misfolded proteins. It’s possible that oligomeric misfolded -syn 
is the main player in the SNpc DA neurons degeneration and the Lewy body formation is 
just a consequence of this process100,153–157. To better investigate this hypothesis, 





2.3.2 Mitochondrial dysfunction correlated with oxidative stress hypothesis 
 
An alternative and not mutually exclusive hypothesis for PD neurodegeneration is based on 
mitochondrial dysfunction correlated with oxidative stress158. 
Studies of different forms of PD including familial early-onset PD (characterized by mutations 
in DJ-1, PINK1, and parkin genes), dominant forms of PD (characterized by mutations in 
LRRK2, SNCA and CHCHD2 genes) and non-familial PD (characterized by toxin exposure) 
all show direct involvement in mitochondrial biology, influencing a range of functions from 
oxidant defenses, to quality control and oxidative phosphorylation (OXPHOS)159–162. 
DA neurons have three features that make them preferentially vulnerable to these insults:  
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- Long and highly branched, unmyelinated axons with an extraordinary number 
of transmitter release sites. Mitochondrial oxidative stress is higher in long axons 
and this causes the axons to decrease in length163. The large axonal arbor and high 
number of transmitter release sites in DA neurons results in a higher expression of 
the -syn synaptic protein, giving the potential for a synuclein pathology164.  
- A specific physiology with slow and broad action potentials that promotes 
rhythmic activity165. This physiology fulfills two functions, it maintains slow tonic 
spiking by creating membrane potential oscillations166 and it promotes calcium entry 
into mitochondria to stimulates oxidative phosphorylation (OXPHOS) and the 
production of ATP167. These functions can lead to mitochondrial damage, ROS 
formation, alteration of the autophagy mechanisms and accumulation of misfolded 
proteins like -syn168,169. 
- Usage of dopamine as the preferential neurotransmitter. Dopamine is known to 
be potentially toxic because it oxidizes to reactive DA quinones. DA quinones are 
demonstrated to disrupt the function of glucocerebrosidase (GC) and lysosomes; 
mechanisms related to neurodegeneration170–172. Dopamine also causes 
mitochondrial alterations through the mitochondrial anchored monoamine oxidase 
(MAO). The MAO degrades cytosolic dopamine, generating hydrogen peroxide and 
increasing ROS173.  
The impaired mitochondria become unable to produce energy and this leads to an 
imbalance in dopamine (DA) vesicular storages, further increasing ROS174,175. 
Given their extraordinary number of transmitter releasers, DA neurons are per se more 
vulnerable to stress and dysfunction that can contribute to neurodegeneration. 
Many mechanisms are involved in the preferential neurodegeneration of the dopaminergic 
neurons during PD but still no research has been able to highlight which one is the most 
prevalent or the causal order. New models that mimic the slow progression of the disease 
are needed to test hypotheses about the mechanisms underlying pathogenesis and to 
connect patient’s motor symptoms of PD to the stages of degeneration of SNpc DA neurons. 
 
3. Modelling PD 
 
Our understanding of the relationship of genetic targets with the cellular mechanisms that 
drive neuronal death in PD is still very fragmentary, making it challenging to create and test 
therapies which work in models and in clinical trial. The models used often have poor 
predictive power to determine the human clinical success of a given drug because of the 
model’s relative simplicity compared to the systemic complexity of the disease176. 
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3.1 Animal and cellular PD models 
 
Investigating systemic diseases like PD requires different techniques to address the 
pathogenic role of newly identified mutations including overexpression or knockdown of the 
gene of interest in vitro and in vivo. Traditionally engineered animal and cellular models have 
several limitations:  
a. cellular models mainly use standard human tumor cell lines and therefore only 
partially reflect the characteristics of non-dividing human DA neurons177,178;  
b. genetic animal models based on overexpression (driven by non-native or 
physiological human promoters) or knockout of the gene of interest, only partially 
replicate key features of neurodegeneration in PD. 
These limitations (and others) mean that traditional animal and cellular models are not ideal 
for a comprehensive and systemic picture of this complex neurodegenerative disorder. 
Patient-derived fibroblasts have also been used to investigate cellular and molecular 
mechanisms of PD, but they too have some disadvantages:  
a. fibroblasts change their clonal composition during passaging in culture;  
b. -syn, which encodes the hallmark protein of PD pathology in neurons, is only 
marginally expressed in fibroblasts. 
A systemic approach can be achieved with animal models of PD. Animal models based on 
the systemic or local administration of neurotoxins easily and rapidly replicate DA 
neurodegeneration, but they fail to capture the slow and progressive degenerative changes 
that occur in human PD pathology. Genetic animal models of PD often do not show all signs 
and symptoms of the disease. 
Although cellular and animal models of PD provide insights into alterations in specific 
subcellular components (such as proteasome, lysosome and mitochondria), the relevance 
of these findings for PD pathogenesis is not always immediate, as they do not address the 
increased susceptibility of DA neurons to undergo PD-related neurodegeneration179.  
 
Table 3. PD related animal models 
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3.2 Induced pluripotent stem cells (iPSC) 
 
 
Fig. 4 This diagram represents the potential therapeutic applications of iPSCs in PD studies. iPSCs can be 
reprogrammed using different techniques suited to different applications such as transplants or in vitro study. 
The most commonly used reprogramming techniques are: viral delivery (retroviruses and adenoviruses), 
integrative free vectors (piggyBac transposon, plasmid/episomal plasmid vectors, mini-circle vectors) and 
non-integrating methods (direct protein/microRNA delivery, small molecules). iPSCs from PD patients and 
healthy age-matched controls can be corrected/edited to receive patient-specific mutations suitable for clinical 
application. This figure uses PD as an example of the potential therapeutic uses of iPSC but the mechanisms 
of this are common to many other pathologies. iPSC disease modeling is particularly important for neural 
diseases because of the difficulties in reaching the affected neural tissue in patients.  
From: C.Calatayud et al. (2017). DOI: 10.1016/j.gde.2017.06.002213 
Induced pluripotent stem cells (iPSC), generated from patients with genetic conditions, can 
be exploited to create genuinely human experimental models of diseases 214. Modeling 
human disease using iPSC technology involves two steps: the generation of iPSC from 
representative patients, and the differentiation of patient- specific iPSC towards disease-
relevant cell type(s). The major advantage of the iPSC approach is the potential to develop 
human cell-based disease models of sporadic and genetically complex diseases such as 
PD.  
PD is very interesting model for application of iPSC technology, because protocols for 
generating DA neurons are relatively robust and reproducible215–217. Studies from our group 
and others using iPSC derived from patients with monogenic forms of PD have proven that 
key features of PD pathophysiology as a late-onset neurodegenerative disorder can be 
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modeled after differentiation into dopaminergic neurons. Specifically, it was demonstrated 
not only that iPSC technology can be used to observe phenotypes relevant to 
neurodegeneration in PD, but also that iPSC-derived neurons with the genome of sporadic 
PD patients exhibited similar phenotypes to those seen in iPSC derived from patients with 
monogenic PD213,217–220. iPSC technology may also facilitate identification of therapeutic 
compounds by elucidating authentic signaling pathways in diseased human neurons rather 
than artificial models. For example, Cooper et al.221 focused on mitochondrial functions in 
PD associated with mutation in PINK1 and LRRK2 genes. They found that iPSC-derived 
neurons are more sensitive to the chemical toxins valinomycin and concanamycin A. 
Subsequently, the iPSC-derived neurons treated with the antioxidant coenzyme Q10, 
rapamycin or the LRRK2 inhibitor GW5074 resulted in partial protection against neural 
degeneration.  
Clinical application of iPSC-derived neurons for treatment of PD is still a distant option. The 
challenge for a more comprehensive study of epigenetic and genetic characteristics of iPSC-
derived neurons mainly lies in the necessity to generate a cell population that allows 
purification based on highly specific midbrain DA markers. An outstanding concern is 
whether it is prudent to use a patient’s own cells to derive DA neurons for therapy, in view 
of their presumed susceptibility to developing PD pathology. To date, iPSC has been an 
excellent tool to investigate neurodegenerative diseases like PD but its application in clinical 
and therapeutic usage requires further analysis for completeness and stability222. 
 
4. Studying neurodegenerative diseases with calcium imaging 
 
Neurodegenerative diseases like PD, Alzheimer’s disease and other types of dementia are 
in the top five causes of death worldwide, in the top 3 if we consider only high-income 
countries223. Tremendous efforts are being taken to cure these diseases, but clinical 
researchers have made very limited progress due to the difficulties in studying the etiology 
and pathophysiology of these disorders. As already mentioned, the lack of robust animal 
models and the difficulties in obtaining early human samples make the investigation of 
neurodegenerative causes even harder.  
Calcium imaging techniques have been widely applied to study neuronal behavior and have 
given the scientific community important insights to understand the physiology and 
pathophysiology that relates to these cells224–226. 
The possibility to capture images and record the live motion of calcium ions in neurons 
allows the investigation of different mechanisms connected with this type of cell. In the 
synaptic terminals, calcium influx regulates exocytosis227 and the synaptic plasticity that 
happens in response to a stimulus228. In cell nuclei, calcium is able to regulate gene 
transcription229 and overall in the neurons it is the sign of an event of action potential230 
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because the Са2+ channels connect the “electrical” and the “signaling” worlds in the 
neurons231.  
 
4.1 Calcium imaging techniques 
 
Calcium imaging requires the use of two techniques working together to allow robust and 
repeatable results:  
a. the development and continuous improvement of calcium sensors; 
b. the development and the implementation of the appropriate instrumentation to 
detect and record the calcium fluctuations.  
Bioluminescent calcium-binding photoproteins, such as aequorin232,233,  were the first 
proteins to be discovered and applied to achieve this goal. The implementation of these 
indicators was slow due to problems of dye delivery. Tsien and colleagues succeeded in 
developing the first generation of fluorescent calcium indicators consisting of quin-2, fura-
2, indo-1, and fluo-3234. Among these, fura-2 was considered particularly useful because 
more quantitative calcium measurements were able to be detected235 with this marker. An 
important next breakthrough, again from the laboratory of Roger Tsien236, was the 
introduction of protein-based genetically encoded calcium indicators (GECIs). These were 
optimized and made more user friendly by Looger and Griesbeck and Rochefort et al237,238. 
The development of new imaging techniques evolved in parallel with the discovery of 
calcium binding photo proteins and dyes. This included the implementation of video 
imaging239,240, charge-coupled device (CCD) cameras241 and high-speed confocal 
microscopy242 for calcium imaging. The introduction of two-photon microscopy in the early 
1990s, by Winfried Denk and colleagues, represented a major advance in calcium imaging 
of the nervous system243,244. 
 
4.2 DA neurons, calcium homeostasis and electrophysiological characteristics 
 
Ventral midbrain dopaminergic neurons located in the SNpc have a distinctive physiological 
phenotype. They are autonomously active and generate action potentials in a clock-like 
manner even without synaptic inputs. This capability is called pacemaker activity245. They 
also display an elevated intracellular Ca2+ concentration due to the fact that they use ion 
channels to allow the Ca2+ to enter the cell246,247. Cav1.3 pore-forming subunits are the 
channels used by DA neurons to evoke pacemaker action potentials. They are relatively 
rare, constituting only 10% of all the L-type Ca2+ channels found in the brain248. They have 
the capability of opening at relatively hyperpolarized potentials, enabling them to push the 
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cells to spike thresholds249. The sustained engagement of Cav1.3 Ca2+ channels during 
pacemaker activity comes at a great metabolic cost to the SNpc DA neurons. To avoid 
cellular stress and damage, Ca2+ entering the neurons is rapidly sequestered or pumped 
back across the steep plasma membrane concentration gradient. To do so it’s necessary to 
use energy stored in ATP or in ion gradients that are maintained with ATP-dependent 
pumps. The two organelles most responsible for handling the Ca2+ crossing the plasma 
membrane are the same two organelles most closely linked to PD: the ER and the 
mitochondrion246,250.  
 
Fig 5.From: C. Chan et al. (2009). DOI: 10.1016/j.tins.2009.01.006250. 
As distinctive as the physiological phenotype is the electrical activity of SNpc DA neurons. 
This activity is a consequence of the calcium oscillation in the dendrites of the neurons and 
is modulated by a complex and intricate interplay of distinct ion channels, transporters, and 
receptors. It is crucial for presynaptic and somatodendritic dopamine release, and hence for 
all dopamine-mediated functions251. The electric activity of DA neurons is further modulated 
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by dopamine, creating a negative feedback loop, by activation of the G-protein coupled K+ 
channels (GIRK2) via dopamine auto-receptors of the D2-type (D2-AR). 
 
4.3 Electrophysiological PD studies in animal models 
 
Even though PD animal models do not optimally resemble all the characteristics of the 
disease, many studies have been performed to better understand the pathophysiology of 
dopaminergic neurons before the neurodegeneration. 
A rotenone rat model was described as causing a syndrome that replicates both 
neuropathological findings and the behavioral symptoms of PD. Von Wrangel and 
colleagues185 were able to reproduce PD specific motor phenotypes and selective loss of 
DA neurons in the SNpc. Interestingly, the study reveals that the loss of dopaminergic 
neurons after exposure to rotenone creates a specific electrophysiological phenotype on the 
connected neurons of the striatum: 
- STN neurons discharged with a significantly higher firing rate 
- STN neurons discharged with significantly more bursts per minute in the rotenone 
treated group 
- STN neurons discharged with a highly entropic firing pattern 
This study suggests that the loss of connection between two groups of neurons that are 
normally related can cause alterations in their activity causing hyper-activation and hyper-
bursting behavior. These are known to generate stress and alter the functionality of the cells. 
In another study, a mouse model with LRRK2 G2019S knock-in mutation was developed. 
LRRK2–G2019S mice generate abnormally elevated excitatory activity and altered spine 
morphology in dorsal striatal spiny projection neurons that is kinase dependent, a gain-of-
abnormal activity that is outside the normal role of LRRK2 function. This paper confirms the 
previous data showing an alteration in the electrical and physiological activity of neurons 
connected with DA neurons. The hyperactivity and disorganization of the synapsis are 
phenotypes directly caused by PD related mutation252. 
MitoPark mice are a recently developed genetic model of PD that lacks the gene for 
mitochondrial transcription factor A in dopaminergic neurons. Using a MitoPark mouse, 
Branch and colleagues253 investigated the activity of DA neurons in brain slices in order to 
obtain insight of the specific behavior of these cells before neurodegeneration. This model 
mimics many distinct characteristics of PD including progressive and selective loss of SNpc 
DA neurons, motor deficits that are improved by L-DOPA and development of inclusion 
bodies210. Using patch clamp technique, they were able to demonstrate multiple examples 
of declining functionality in single dopaminergic neurons across a range of ages; in particular 
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they show the disruption of the pacemaker activity, an increase in firing rate and a reduction 
in the firing peak and amplitude. DA neurons in the MitoPark mice also show a disruption in 
the presynaptic and postsynaptic vesicle systems, especially related to dopamine. All of 
these characteristics are consistent with the PD phenotype. 
  
4.4 Human studies 
 
One of the main goals of neuroscientists is to find the quickest, least invasive and most 
accurate way to obtain and automatize an early diagnosis of neurological diseases using 
molecular, structural and functional neuroimaging modalities254. Known examples exist for 
Alzheimer's disease255–257, epilepsy258, alcoholism259, attention-deficit hyperactivity 
disorder260 and major depressive disorder261. Searching for applications of these techniques 
for the early diagnosis of PD is a natural next step. Positron emission tomography (PET), 
functional magnetic resonance imaging(fMRI)262,263, transcranial sonography264, 
magnetoencephalography265 or single-photon emission computed tomography are currently 
used to examine the dopaminergic system of the brain of PD patients to understand the 
pathophysiology. To identify alterations in early PD’s patient brains, researchers try to find 
disorganization in the brains functional or effective connectivity266. Functional connectivity is 
defined as a temporal correlation between spatially remote neurophysiological events, 
whereas effective connectivity is defined as the influence that one neuronal system exerts 
over another267. It has been demonstrated that cases of PD combined with dementia are 
often correlated with a disruption of both functional and effective connectivity in the cortex268. 
Another symptom associated with PD is depression, which has been shown to be connected 
with disrupted functional connectivity between the median cingulate cortex and the 
precuneus, prefrontal cortex, and cerebellum269.  
There are many other examples that demonstrate altered connectivity between brain areas 
causing PD motor and non-motor symptoms. A recent publication proved, for the first time, 
a substantial change in the dynamic connectivity of PD patients’ brains. Jinhee Kim and 
colleagues analyzed 31 PD patients and 23 healthy, age-matched controls and they 
observed two discrete connectivity configurations: 
a. a more frequent, sparsely connected within-network state (State I), and 
b. a less frequent, more strongly interconnected between-network state (State II). 
Interestingly, patients with PD show a significant decrease in the occurrence of the sparsely 
connected State I (-12.62%), while the expression of the more strongly interconnected State 
II increased by the same amount. This phenotype seems to correlate with the clinical severity 
of PD symptoms and suggests a reduction in functional segregation among networks. The 
paper also describes a higher variability in PD network global efficiency and abnormal global 
integration of brain networks. These phenotypes confirm that the connectivity of a PD brain 
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is more vulnerable and displays higher susceptibility to stress and is overall more likely to 
display degeneration270.  
 
5. iPSC disease modelling and calcium imaging 
 
As discussed previously, it is not yet known the extent to which neurodegeneration in PD 
results from intrinsic or cell-autonomous mechanisms, or whether non-neuronal cell types 
such as astrocytes or microglia play important roles in this process. The use of iPS cell 
technology, which allows the generation of different cell types from the same patient, makes 
possible the investigation of the impact of cell types other than DA neurons, for the first time. 
One of the main issues for modeling pathologies in vitro is the difficulty in obtaining the 
relevant cell type and producing an abundant number of differentiated cells to study early 
signs of neurodegeneration and test therapeutic treatments. To do this, we used a previously 
published protocol216 that mimics the stages and processes of ventral midbrain DA neuron 
maturation, whilst applying an appropriate combination of growth factors and signaling 
molecules to develop this area of the brain in vitro. 
Having successfully differentiated the iPSC to A9 DA neurons, those susceptible to 
neurodegeneration in PD, using calcium imaging techniques we can study the dynamic and 
functional behavior of these cells over a defined period of time that precedes the 
morphological degeneration. The data collected with this technique allow us to examine and 
visualize the evolution of connectivity in the A9 DA neuron cell culture and highlight the 







Using iPSC derived from PD patients, we have created a proven in vitro model of the 
pathological phenotypes of PD217. Being able to reproduce PD phenotypes in a controlled 
environment gives us a unique opportunity to study the steps that precede 
neurodegeneration. We know from the literature that PD develops over the course of 20 
years or more and that PD patients go through a period in which the DA neurons start to 
degenerate but no outward signs and symptoms are displayed. During this period the small 
percentage of DA neurons that are still not affected by the disease are capable of 
maintaining the physiological duties of the SNpc. This suggests that while some DA neurons 
are dysfunctional others are still healthy and are affected later.  
 
 




Our model demonstrates the major neurodegenerative events, such as the synuclein 
accumulation and the selective loss of DA neurons in vitro. This allows us to undertake a 
comprehensive and multidimensional investigation to study this early phase of the disease 
where functional degeneration has started but is not yet systemic or symptomatic. The goals 
of this study are: 
 
1. To identify early functional alterations in DA neurons differentiated from PD patient-
specific iPSC: 
a. establish a robust cell culture system to derive human midbrain specific 
progenitor cells in order to obtain ventral midbrain dopaminergic neurons; 
b. study the spontaneous functional behavior of ventral midbrain DA neurons 
from PD patient specific lines compared to controls; 
c. individuate biological and molecular targets connected with functional 
impairment applying a gene expression profiling technique. 
 
2. To investigate whether DA neurons degeneration in PD is truly a cell-autonomous 
phenomenon, or whether it is influenced by an altered cross talk between ventral 




MATERIALS and METHODS  
 
1. iPSC information 
 
We used 6 iPSC lines previously generated and characterized in our laboratory, as previously 
described217,271. These comprise one iPSC line obtained from a healthy donor (SP11) and two other 
lines obtained from Parkinson’s disease patients carrying the LRRK2 G2019S mutation (SP12 and 
SP13). From these original lines, isogenic controls, differing in the presence of the LRRK2 G2019S 
mutation, were obtained by correcting the mutation to the SP12 iPSC line and by knocking-in one 
mutant allele into the wild type SP11 control iPSC line. Two Tyrosine Hydroxylase reporter iPSC lines 
were also generated by gene editing from the same parental SP11 and SP12 iPSC lines. 
 
Table 4. Information on PD patients, controls and iPSC lines used in this study 





Controls SP11#1 F 48    
SP11#1 TH F 48    
SP12#3 ED F 63 49 Yes LRRK2 (Corrected) 
SP13#4 ED F 68 57 Yes LRRK2 (Corrected 
Mutants SP12#3 F 63 49 Yes LRRK2 
SP13#4 F 68 57 Yes LRRK2 
SP12#3 TH F 63 49 Yes LRRK2 
 




As described by Sanchez Danes et al.271 a biopsy of keratinocytes or fibroblasts from PD 
patients and aged matched controls were cultured in serum-free low calcium medium and 
reprogrammed using a 1:1:1 mix of retro-viruses encoding FLAG-tagged OCT4, SOX2 and 
KLF4. A specific medium was used to select the reprogrammed cells composed by KO-
DMEM (Invitrogen) supplemented with 20% KO-Serum Replacement (Invitrogen), 2 mM 
Glutamax (Invitrogen), 50 mM -mercaptoethanol (Invitrogen), non-essential amino acids 
(Cambrex) and 10ng/ml FGF (Peprotech). The selected cells acquired pluripotency 
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features. The cells were maintained at 37ºC, 5% CO2 and the medium was changed every 
day. After 45/60 days, colonies that resemble iPCS morphology were manually picked and 
plated on top of human fetal fibroblast for at least 10 passages in order to remove the 
residual virus. Stock of iPSCs on feeder layers were cryopreserved and stored as a 
backup. After 10 passages on the feeder layer, iPSCs were manually passed on top of 
Matrigel coated plates and maintained in mTeSRTM medium to preserve the pluripotency. 
Another 5 passages, using Accutase enzyme, were carried out to adapt the iPSC to 
Matrigel condition. All the experiments were done using Matrigel adapted iPSC. These 
lines were characterized fully for pluripotency in the previous cited paper.  
 
3. Evaluation and amelioration of neuronal generation protocols and NPCS 
 
We tested multiple different protocols that could be used to obtain an enriched culture of DA 
neurons as these are the neuronal population that is most relevant for the study of PD. 
Crucial for the aim of my project was to have a feeder’s free culture to allow us proper usage 
of the calcium imaging assay.  
The best working protocol to generate DA neurons is derived from the one published by 
Kriks et al216. I set up and adapted the protocol to our line and cell culture conditions.  
 
3.1 Generation of ventral midbrain precursors from monolayer 
 
 
Fig 7. Schematic representation of the first steps of the floorplate protocol that we used to differentiate iPSC 
into ventral midbrain specific DA NPCs.  
 
Kriks et al. have developed a new protocol based on the neurodevelopmental steps that 
happen during the embryogenesis in vivo. This protocol is based on culturing iPSC in 
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conditioned medium HES or mTeSR commercial medium until they reach 80% confluence. 
Then ventral midbrain induction is forced by switching to SRM medium (KO-DMEM, 15% 
KO serum, 1%P/S, 1% glutamine, 1% NEAA, 0,1% beta mercaptoethanol) with SB Tocris 
1614 (selective inhibitor of the grow factor TGF-), LDN193189, Stemgent 04-0074 (BMP 
inhibitor) to inhibit the dual SMAD pathway, SAG and Purmorphamine, Calbiochem 540220 
(SHH pathway activators) to induce neuroepithelial stem cells formation and proliferation. 
Next the medium is changed to Neurobasal with 1% P/S, 1% N2 and 2% B27-VitA and 
CHIR99021, Stemgent 04-0004 (CHIR), a potent GSK3B inhibitor known to strongly activate 
WNT signaling that induces LMX1A in FOXA2 ventral midbrain dopaminergic neuron 
precursors. We used this combination to induce dopaminergic differentiation of midNESC, 
with some modifications. We fix in PFA 4% (paraformaldehyde) culture the cells for 11, 12, 
13, 14, 15 day to check the best co-localization between FoxA2 and Lmx1A.  
 




Fig 8. Schematic representation of the first steps of the alternative protocols that we apply to generate ventral 
midbrain specific DA NPCs 
 
In parallel we tested another protocol published by A. Kirkeby and derived from Kriks’s 
protocol. We performed this test to verify if this method allows us to obtain a greater 
population of vmDA neurons. We used the same medium, which we use for the monolayer 
floorplate protocol. Instead of plating the iPSC as a monolayer this protocol required the 
formation of EBs (embryoid bodies). These are cultured for 5 days in suspension, and then 
selected neural structures were disaggregated and plated. Following the precursor 
generation we fix in PFA4% the culture at D11 to D15, and verify again the best co-
expression of FoxA2 and Lmx1A. This protocol showed a lower efficiency and was not used 





4. Generation of DA neurons using monolayer progenitors 
 
 





Fig 11. Schematic representation of the last steps of the floorplate protocol that we used to differentiate NPCs 
into ventral midbrain DA neurons. 
 
After generating and characterizing the ventral midbrain DA precursors, these cells were 
cultured in Neurobasal medium, 1% P/S and 2% B27-VitA with neurotrophic factors:  the 
transforming growth factor family (TGFβ2/3) Peprotech (Poulsen et al., 1994; Roussa et al., 
2009); members of the neurotrophin family, such as brain-derived neurotrophic factor 
(BDNF) Peprotech (Frim et al., 1994; Hyman et al., 1991); glial cell-line-derived neurotrophic 
factor (GDNF) Peprotech (Akerud et al., 2001; Arenas et al., 1995; Beck et al., 1995; Choi-
Lundberg et al., 1997; Gash et al., 1996; Kordower et al., 2000; Lin et al., 1993; Rosenblad 
et al., 1998; Tomac et al., 1995); and other compounds such as AA (ascorbic acid) known 
to increase the expression of genes involved in neurogenesis, maturation, and 
neurotransmission (Neuroreport. 2004 Aug 26;15(12): 1959-63. Ascorbic acid responsive 
genes during neuronal differentiation of embryonic stem cells. Shin DM1, Ahn JI, Lee 
KH, Lee YS, Lee YS.); DAPT Tocris 2634, γ-secretase inhibitor (Notch inhibitor); dbcAMP 
Calbiochem, dibutyryl cyclic adenosine monophosphate, known to increase neuronal 
survival and differentiation. 
At D20 the precursors were split into wells previously coated with Poly Ornithine (15 ug/ml 
left in it overnight and washed 3 times in DPBS), human Laminin (1 µg/mL filtered and left 
overnight) and Fibronectine (2 µg/mL left in overnight); all of which were diluted in DPBS. 
The number of cells plated for each well is important because it influences the survival of 
the culture (100,000 cells in 24 well plates and 1*106 cells in 6 well plates). The neurons 
were plated using the center-plating technique. 
Cells were differentiated for 15, 30 and 60 days (D35, D50 and D80), fixed in PFA 4% and 
characterized for ventral midbrain DA specific markers like TH, Girk2 (G-protein in DAn), 
DAT (dopamine transporter) and FoxA2 (transcriptional activator for DAn differentiation) and 
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mature neuron markers like MAP2. Other neural markers were tested: 5-HT, GABA, 
Calbindin and GFAP to verify if there was contamination from other neural populations. 
 
5. TALENTs and CRISPR/Cas9 edited lines generation: Isogenic line isoPD1 (SP12#3) and 
isoPD2 (SP13#4) 
 
For correcting the LRRK2 G2019S mutation, iPSC from PD1 (SP12#3) and PD2 (SP13#4) 
were gene-edited using TALENs. iPSC are grown to confluence in 10cm plates. 2-4 hours 
before the gene editing procedure they are treated with 10 µM Y-27632 (RI; Miltenyi-
Biotech).  After two to three hours, iPSC were disaggregated to small clumps using Accutase 
(eBiosciences), re-suspended in ice-cold cHES medium supplemented with RI and 
containing 15 µg of each TALEN monomer-coding plasmids and 30 µg HDR donor template 
and placed in an electroporation cuvette. Cells were electroporated with a Gene Pulser Xcell 
electroporation system (BioRad) set to 250 V and 500 µF (time constant should be between 
10 and 14 milliseconds). After being pulsed, the cell suspensions were seeded in 10 cm 
plates coated with Matrigel containing RI-supplemented cHES medium. 72 hours post-
transfection, 50 µg/mL G-418 (Melford Laboratories Ltd.) treatment was initiated and 
maintained for 2 weeks until resistant colonies attained enough size to be screened. At that 
moment, half of each resistant colony was manually picked and site-specific integration was 
verified by means of PCR and Sanger sequencing assessed gene correction. The clones 
were expanded, cryopreserved and karyotyped. 
 




Fig 15. Scheme describing the recombination steps during the editing process. Blue arrows represent the 




We edited CTR (SP11#1) and PD1 (SP12#3) lines with CRISPR/Cas9 plasmid 
pSpCas9(BB)-2A-GFP (PX458)272  obtained from Addgene (#48138). The original pCbh 
promoter was exchanged for the full-length pCAGGS promoter in order to achieve higher 
expression levels in iPSC. Custom guide RNAs were cloned into the BbsI sites as annealed 
oligos.  
For the TH donor template, homology arms were amplified from genomic DNA and verified 
by Sanger sequencing. Resulting sequences matched those of the reference genome 
GRCh38. They were inserted into the KpnI-ApaI (5’HA) and SpeI-XbaI (3’HA) sites of pBS-
SK(-). P2A peptide was added to mOrange, with the primers used to amplify the gene, and 
the PCR product was inserted into the ApaI-XhoI sites of the pBS-5’HA-3’HA plasmid. 
Finally, pRex1-Neo-SV40 was inserted between the XhoI and SpeI of the previous plasmid. 
For the generation of TH reporter iPSC cell lines, iPSC are grown to confluence in 10cm 
plates and co-transfected with 6 µg of CRISPR/Cas9 plasmid and 9 µg HDR template using 
FuGENE HD (Promega) at a 1:3 DNA to reagent ratio. 72 hours post-transfection, 50 µg/mL 
G-418 (Melford Laboratories Ltd.) treatment was initiated and maintained for 2 weeks until 
resistant colonies attained enough size as to be screened. The colonies that contain the 
genetic reporter are selected and we proceed with the excision of the selection cassette. 
Edited iPSC are transfected with CRE recombinase-expressing plasmid (gifted from Dr. 
Michel Sadelain - Sloan Kettering Institute; Addgene plasmid #27546). 48 hours post-
transfection, cells were singularized and seeded at clonal density on a feeder layer of 
irradiated human fibroblasts. Once colonies attained a certain size they were picked and 
cultured in independent matrigel-coated wells. Cells were sampled and checked for cassette 
excision by PCR and Sanger sequencing. Those clones in which the cassette was excised 
were expanded, cryopreserved and karyotyped. 
 
5.2 TALENTs and Crispr/Cas9 edited lines differentiation 
 
DA neurons were generated from the edited lines (both isogenic and TH reporter) using the 
same protocol described above with minor modifications. We noticed that these cells were 
more likely to die during the differentiation, so we decided to change little details during the 
first step of precursor generation and the final step of DA neuron differentiation and 
maturation to increase the survival and the ventral midbrain differentiation efficiency. 
Briefly, instead of switching the medium abruptly we gradually passed from SRM medium to 
NBN2B27-VitA during D5 to D9 of progenitor induction. We maintained CHIR in the medium 
until D20 and we split the progenitors using Rock inhibitor (Miltenyi). The next day, half of 
the medium was changed and from that day on CHIR was removed.  
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As well as the previous non edited lines, at D20 the precursors were split into wells 
previously coated with Poly Ornithine (15 ug/ml left in it overnight and washed 3 times in 
DPBS), human Laminin (1 µg/mL filtered and left overnight) and Fibronectine (2 µg/mL left 
in overnight); all of which were diluted in DPBS.  
Neurons were differentiated for 15, 30 and 60 days (D35, D50 and D80), fixed in PFA 4% 
and characterized for ventral midbrain specific markers like TH, Girk2 (G-protein in DAn), 
DAT (dopamine transporter) and FoxA2 (transcriptional activator for DAn differentiation), 




iPSC in distinct stages of differentiation were used to characterize protein expression using 
immunocytochemistry.  All the cultures were fixed with 4% PFA for 15 minutes, washed 
three times with DPBS for 15 minutes, then washed with TBS1x (low Triton protocol for 
vesicles specific antibodies) or with TBS1+ (with 0.3% Triton for standard protein 
immunocytochemistry) 3 times for 15 minutes and then blocked for 2 hours with TBS+ with 
0.1% Donkey Serum with 0.3% Triton or 0.01% Triton depending on the normal or low Triton 
protocol. Primary antibodies were incubated for 48 hours at 4ºC. After 48 hours incubation 
with the primary antibody, samples were washed with TBS 1x/TBS+ for 15 minutes three 
times. Then the blocking was repeated for 1 hour at room temperature followed by 2 hours 
incubation with the secondary antibodies (all at a dilution of 1:200). The samples were 
washed with TBS 1x for 15 minutes three times and then incubated with nuclear staining 
DAPI (Invitrogen, dilution 1:5000 in TBS1x) for 10 minutes. After washing twice the DAPI 
with TBS1x samples were mounted with PVA:DABCO, dried for 2 hours at room temperature 
and stored at 4ºC until imaged. Samples were imaged using an SP5 confocal microscope 
(Leica®) and analyzed with FIJI® Just ImageJTM®. The following antibodies were used: 
Table 5: Information on primary antibodies used in this study 
Antibody Species Reference Dilution Low Triton 
MAP2   anti-Rabbit Santa Cruz sc-20172 1:1000 NO 
GIRK2  anti-Rabbit   Sigma P8122 1:40 NO 
FOXA2 anti-Mouse   R&D Systems (AF2400) 1:250 NO 
LMX1A anti-Rabbit Millipore (AB10533) 1:1000 NO 
Engrailed (D-20) anti-Goat Santa Cruz (sc-46101) 1:200 NO 
Nestin anti-Rabbit Chemicon (AB5922) 1:250 NO 
α-synuclein anti-Mouse BD, 610787 1:500 SI 
TH anti-Sheep   Pel-Freez, P60101-0 1:500 NO 
TH anti-Rabbit   Santa Cruz, sc-14007  1:250 NO 
DAT anti-Rat Chemicon (MAB369) 1:300 YES 
RFP anti-Rabbit Abcam (ab34771)  1:400 NO 
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Table 6: Information on secondary antibodies used in this study 
Antibody Species Product Code 
Alexa Fluor 488  anti-Mouse IgG Jackson 715-545-150 
Cy3  anti-Rabbit IgG Jackson 711-165-152 
DyLight 649  Anti-Mouse Jackson 706-495-148 
Alexa Fluor 647  anti-Sheep Jackson 713-605-147 
Cy3 anti-Rat IgG Jackson 712-165-153  
Cy™2 AffiniPure Donkey  Anti-Rabbit IgG (H+L) Jackson 711-225-152 




7. Neurite quantification 
 
The images were analyzed using the program NeuronJ® to quantify the length and 
differentiate the type of neurite for both TH+ and MAP2+ cells. For each neuron, primary, 
secondary and tertiary neurites were highlighted and classified in the program and each 
trace was automatically measured and organized in order to obtain information for each 
single cell. An average of 5 images with 10 neurons in each image at each timepoint was 
quantified for TH+ analysis. 5 images with 5 neurons in each image at each timepoint were 
used to extract the MAP2+ data. 
 
8. Calcium imaging 
 
We used calcium imaging224,225,273,274 to evaluate the differences in spontaneous activity 
between healthy and PD neurons. Calcium imaging allows the monitoring of a large 
population of neurons, simultaneously and non-invasively, which makes it particularly 
suitable for whole network analyses. Living neurons were incubated for 30 minutes in a 
solution that contained 3ml of recording medium (EM, consisting of 128 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, 45 mM sucrose, 10 mM glucose, and 0.01 M Hepes; treated to pH 7.4) 
and 4 µg/ml of the cell-permeant calcium sensitive dye Fluo-4-AM. At the end of incubation, 
we washed the culture with 2 ml of fresh EM to remove residual free Fluo-4. This medium 
was then discarded to place 4 ml of fresh EM, the final medium for actual recordings. The 
culture dish was mounted on a Zeiss inverted microscope equipped with a CMOS camera 
(Hamamatsu Orca Flash 2.8) and an arc lamp for fluorescence. Grey scale images of 
neuronal activity were acquired at intervals of 20 frame per second and a spatial resolution 
of 4.40 μm/pixel. Images had a size of 960 × 720 pixels with 256 gray-scale levels. The latter 
settings provided a final field of view of 2.8x2.1 mm that contained between 300 and 700 
neurons. Cells were imaged in bright field and then for 15/30-minute recordings using 
Hokawo® software275. Next, calcium fluorescence traces were retrieved using customized 
software based on MatLab® First, a manual selection of Regions of Interest (ROIs) was 
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carried out to track the activity of cells that had prototypical neuronal morphology. After 
analyzing the recording, further post-processing allowed the removal of fluorescence traces 
not corresponding to stereotyped neuronal firing (either non differentiated cells or glia). Data 
was finally averaged among the minimum 2 replicates of each time-point. Hence, our results 
are based on a population of at least 500 neurons per time-point.  
Thanks to this program if was possible to obtain all the different information to analyze the 
behavior of the neurons: 
- Clumps and unclear ROIs were excluded, 
- Peaks of calcium fluorescence, 
- Video of the registration, 
- Percentage of active neurons. 
 
8.1 Data analysis 
 
In order to reconstruct the neurons’ activation sequence, we first isolated a particular 
bursting event from the rest of the sequence. Next, for the fluorescence signal of each 
neuron, we carried out two linear fits: one fit of the data points preceding the firing and 
another one of the points encompassing the fast increase in fluorescence. The crossing 
point of the two lines provided the activation time of the neuron. This process was repeated 
for all neurons, and the final activation time dataset was ordered to reconstruct the 




8.2 Network dynamics 
 
We represented the overall neuronal fluorescence activity of each experiment as a raster 
plot in which each neuronal calcium transient, or burst, is plotted as a dot against its 
initiation time. The collective activity of a large set of neurons can be summarized, allowing 
for the fast identification of particular ensemble dynamics such as synchronization in the 
form of hyper-bursting or low-amplitude oscillations. 
 
8.3 Global network activity 
 
We investigated the collective activity of the whole set of studied experiments by analyzing 
their neuronal firing sequences. We summed all the firing events occurring in a sliding window 
of 1s in length (20 frames) and normalized the count by the number of neurons analyzed in 
each experiment (corresponding to selected ROIs), allowing for the computation of the 
Global Network Activity (GNA) of each experiment. 
 
8.4 Extreme events 
 
After computing GNA, we selected the maxima of each GNA trace that had a predefined 
prominence. In this sense, a point was considered a maximum peak if it has the maximal 
value and was preceded (to the left) by a value lower than a threshold amplitude delta. We 
extracted the statistics of GNA amplitudes and considered extreme events to be those 
maxima displaying amplitudes above the average GNA level plus one standard deviation. 
We calculated the z-score for each extreme as: 
z = 
x − µ 
 
          σ 
• x is the value of the maxima,  
• µ is the average maxima height and  
• σ is the standard deviation of the distribution of maxima.  
We considered extreme events to be those peaks with a z-score above 0.96. After 
considering these peaks, we computed the ratio of extreme events by dividing the number 
of peaks matching our criteria by the overall number of peaks found. We also computed the 
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frequency of extreme events by dividing the number of extreme events found by the time 
duration of the experiment in minutes. 
 
8.5 Neuronal networking and functional analysis 
 
To better understand the functional connections between each active neuron we identified causal 
relationships between neuronal firings using measures that identify the flow of information 
between two firing sequences. Besides, we analyzed the functional organization of all 
networks in terms of its fitness to models of hierarchical structures, as explained below. 
 
8.5.1 Effective connectivity analysis 
 
The sequences of neuronal activations give us the information about the degree of causal 
influence between any pair of cells in the network. If the firing of a neuron j concurrently 
follows the firing of a neuron i, the principle of causality establishes an increased probability 
that the activity of i induces the activity of j. The likelihood of this relationship is weighted 
based on the frequency of occurrence along the observational time. Such algorithm 
provides the effective connectivity between neurons in a network.  
 
8.5.2 Closeness to free scale distribution 
 
We hypothesized a scale-free organization of functional networks in the cultures and 
computed how much the retrieved topology diverged from our hypothesis. The model we 
used is an extension of the Barabási and Albert algorithm 276called Initial Attractiveness 
model, which reads: 
pk = C(k + A)−γ.
  
In this model, three parameters control the degree of distribution of a network pk in order  for 
it to display a low degree cut-off, resembling some of the distributions we found in our 
analyses. A is the initial attractiveness parameter, which indicates whether the network is in 
the random network regime (high A) or scale-free (low A). Besides, an exponent γ larger 
than 3 (which particularly corresponds to the standard Barabási-Albert model) is indicative 
of a random network organization. Finally, C provides the ’steepness’ of the probability 
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function in a log-log representation. We fitted our data to this model using the least square 
error method277 and computed the coefficient of determination R2 278. An R2 value close to 1 
denoted a close fit between data and model, whereas a low R2 value represented a bad fit 
between data and model. Since our model generates hierarchical topologies known to be 
characteristic of neuronal networks, we classified our cultures as being topologically 
organized if their functional organization fitted a hierarchical model of degree of distribution 
and disorganized otherwise. 
9. Molecular biology 
 
9.1 DNA and RNA extraction 
 
9.1.1 DNA extraction 
 
Genomic DNA was extracted from cells to verify the correct insertion of the specific plasmid 
in the appropriate locus during the gene editing technique. To obtain genomic DNA 
Ethanol/NaAc precipitation protocol was used. Cells were plated in 96 well plate for the 
screening, gently detached from the plate with 30l of Accutase and 70l of cHES. 50l of 
the cell suspension was re-plated and 50l were placed in another 96 well plates with the V 
bottom and used for genomic DNA extraction and gene editing screening. The rest of the 
cells were re-plated to maintain the colony and be able to identify it if the editing was correct.  
The cells suspension was centrifuged at 1200rpm for 10 minutes to collect the cells on the 
bottom of the well without breaking them. After discarding the medium, 50l of lysis buffer 
(PBS with Proteinase K 50ug/mL and 1.7 uM of SDS) was added in each well and incubated 
over night at 55ºC. The next day 10l of NaAc 3M and 40l of isopropanol were added in 
each well. The plate was then vortexed and centrifuged at maximum speed for 15 minutes. 
The supernatant was discarded and the pellet washed with 100l of Ethanol 70%. A second 
centrifugation at maximum speed for 15 minutes was done and the ethanol was removed. 
The pellet was resuspended in 30l Eluition Buffer (EA) Quiagen and used for PCR and 
Sanger sequencing. 
Plasmid DNA extractions from bacterial culture were obtained following the protocol of the 
Quiagen Mini Kit. 
 
9.1.2 RNA extraction 
 
RNA extraction was performed using the TRIZOL protocol. To optimize the extraction, cells 
were quantified and re-suspended in TRIZOL at a volume of 5 x 106 cells / 1ml TRIZOL. The 
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cell suspension was incubated in TRIZOL at room temperature for five minutes and then 
200l chloroform / 1mL TRIZOL were added. The eppendorf was vortexed for 15 seconds, 
and left at room temperature for 2-3 minutes. From this step on, the samples were 
maintained in ice in order to inhibit the RNAse enzymes physiologically present in the cells. 
Next, we centrifuged the sample at 12,000rpm for 15 minutes at 2-8 ºC. The centrifugation 
allows the sample to separate into three phases visible within the tube. We transferred the 
aqueous phase (top) that contains the RNA to a fresh tube, being careful not to contaminate 
the solution with the other phases. Contamination will be obvious by the presence of any 
flakes or unclear liquid. 
500ul isopropanol /1ml TRIZOL (previously used) was added to the new tube and incubated 
in ice for 10 minutes so the RNA could precipitate. The samples were centrifuged at 
12,000rpm for 10 minutes at 2-8ºC. The supernatant was removed and the pellet was 
washed with 500l 80% EtOH. The samples were centrifuged again at 7,500rpm for 5 
minutes at 2-8ºC. After removing the supernatant it’s important to allow the remaining 
Ethanol to air dry for 2-3 minutes. Dissolve the pellet in RNAse free water from Quiagen. 
These samples were used to generate cDNA and perform qPCR to characterize the ventral 
midbrain dopaminergic neurons culture. 
 
9.1.3 RNA extraction for gene expression profile with nanoString nCounter 
 
To perform gene expression profile analysis RNA was extracted from D50 DA neurons using 
RNEasy mini kit from Qiagen. Briefly cells were washed with DPBS, lifted with a scraper and 
collected in a DPBS suspension. The cells were quickly centrifuged for 15 seconds to avoid 
any membrane rupture and the supernatant was removed. The cells were disrupted by 
adding 350l Buffer RLT Plus. The cells were vortexed for at least 1 minute in order to obtain 
a homogeneous lysate. The homogenized lysate was transferred into a gDNA Eliminator 
spin column placed in a 2ml collection tube, centrifuged for 30 seconds and the flow-through 
with the RNA was saved. 350l of 70% Ethanol was added and up to 700 l of the sample, 
including any precipitate that may have formed, was transferred to an RNeasy spin column 
placed in a 2ml collection tube. The column was centrifuged several times and washed with 
different buffers to ensure the purification of the RNA. The RNA conserved in the filter of the 






In our standard PCR protocol we mix all the components in a PCR thin walled 0.2ml tube 
with a final volume of 50l or less. All the reagents were thawed on ice. The reagents were 
added in the following order: water, buffer, dNTPs, MgCl2, template primers, Taq 
polymerase. The reaction tube was gently mixed by tapping and briefly centrifuged to settle 
tube contents. Negative and positive controls were prepared, the first without template DNA, 
the second with a template of known size and appropriate primers. The result of the PCR 
was analyzed by electrophoresis gel. 
 
Table 7: PCR mix components 
Component Final Concentration/Amount 
Water To 50 µl 
Buffer 2 X Or 5x 
Taq Polymerase 0.05 Units/µl 
dNTPs 100 µm 
MgCl2 0.1-0.5 Mm 
Forward Primer 0.1-0.5 µm 
Reverse Primer 0.1-0.5 µm 
Template Depending on the concentration  
 
Table 8: PCR termocycler steps 
Step Temp Time # of cycles 
Initial Denaturation 94°C 5 min   
Denaturation 94°C 30 sec 
30-35 Primer Annealing Tm of primers-5°C 45 sec 
Extension 72°C 1 min per kb 




The isolation of total mRNA was performed using a Quiagen RNA mini kit. One microgram 
was used to synthesize cDNA with the SuperScript III Reverse Transcriptase Synthesis Kit 
(Invitrogen). Quantitative RT-PCR analyses were done in triplicate on 50ng with Platinum 
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Syber Green qPCR Super Mix (Invitrogen) in an ABI Prism 7000 thermo-cycler (Applied 
Biosystems). All results were normalized to GAPDH.  
 
9.4 Sample preparation for gene expression profile with nanoString nCounter 
 
All the steps were done in ice and using the nCounter nanoString reagent for 
Neuropathology panel. The master mix for the hybridization process was prepared by mixing 
hybridization buffer and reporter CodeSet. 
A dilution of 10µg/µl for each RNA to be analyzed was prepared and maintained in ice. For 
each sample a tube was prepared with 5µl of RNA (10µg/µl) and 8µl of master mix. 2µl of 
Capture ProbeSet was added in each tube and the hybridization process was started using 
a PCR machine at 65ºC for at least 16 hours. After this step, the samples were maintained 
at 4ºC. 
Once the hybridization process was completed the hybridized RNA was loaded in the 
neuropathology cartridge and the data were available 24 hours later. 
 
9.5 ROSALIND bioinformatics analysis 
 
Read Distribution percentages, violin plots, identity heatmaps, and sample MDS plots were 
generated as part of the QC step. The limma R library279 was used to calculate fold changes 
and p-values. Clustering of genes for the final heatmap of differentially expressed genes 
was done using the PAM (Partitioning Around Medoids) method using the fpc R library280,281 
that takes into consideration the direction and type of all signals on a pathway, the position, 
role and type of every gene, etc. Functional enrichment analysis of pathways, gene ontology, 
domain structure and other ontologies was performed using HOMER282. Several database 
sources were referenced for enrichment analysis, including Interpro283, NCBI284, KEGG285–
287, MSigDB288, REACTOME289, WikiPathways290 Enrichment was calculated relative to a set 





1. Generation and characterization of neural progenitor cells (NPCs) 
 
Many existing differentiation protocols have a basic DA neuron phenotype (TH-positive cells) 
as the target, but more recent protocols tend to be designed for obtaining DA neurons of a 
specific DA subtype such as A9 DA neurons (TH/GIRK2-TH/DAT-TH/FoxA2 double-positive 
neurons). Even though we can reproduce early developmental morphogenic stimuli and 
differentiate neural progeny from human pluripotent stem cells, many of the cells derived 
from human iPSC remain immature. Differentiation to a specific cell type is unavoidably 
accompanied by contamination with other cell types. Defining the stages and processes of 
DA neuron maturation has an important impact on the cell integration, migration and 
differentiation in transplantation studies. Identifying an appropriate combination of growth 
factors and signaling molecules that mimic as closely as possible the development of the 
human brain is also an important area of investigation.  
We checked our dopaminergic progenitors at different time points to verify the co-expression 
of LMX1A and FOXA2 (Figure 17)  
We obtained the best co-localization staining at D12 so we decided to check the expression 
of the other known markers of ventral midbrain fate at this stage. Both the controls and 
LRRK2-PD lines show a correct expression of the progenitors’ markers. From D0 to D12 
iPSC were cultured in a specification medium that helped them to reach the ventral midbrain 
fate.  
From D12 to D20 the progenitors were cultured in a maturation medium with neurotrophic 
factors that accelerates their maturation. No differences were found between controls and 




Fig 17: Timeline of DA progenitors stained for FOXA2 and LMX1A. Immunocytochemistry of CTR SP11#1 
DA progenitors at different timepoints of differentiation (Day 11, 12, 13, 14 and 15) stained for FOXA2, LMX1A 







Fig. 18: Characterization of D12 DA progenitors. Immunocytochemistry of DA progenitors of CTR SP11#1 
and PD1 SP12#3 at D12 of the differentiation process. The experiments show a consistent expression in both 
lines of ventral midbrain specific markers such as EN1, FOXA2, LMX1A and OTX2. 
 
2. Generation and characterization of DA neurons 
 
At D20 the progenitors were placed on top of cover glass coated with a combination of 
polyornithine, laminin and fibronectin: proteins which reinforce the neuronal differentiation. 
From this day on the neurons are maintained in maturation medium with neurotrophic factors 
for 15, 30 and 60 days (D35, D50 and D80). 
At D50 of the differentiation process, the DA neurons derived from ventral midbrain NPCs 
were analyzed using immunocytochemistry (ICC), in order to obtain a complete 
characterization of the cultures. All the differentiated lines were tested for neuronal markers 
including MAP2 (indicating mature neurons), TH (indicating dopaminergic neurons), 
Calbindin (indicating interneurons A10) and 5-HT (indicating serotonergic neurons). This 
showed: 
a. a full commitment towards mature neurons (~90% of MAP2/DAPI), 
b. a high expression of TH (30-35% of TH/DAPI), 
c. no markers for GFAP astrocytes, 
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d. episodic appearance of other types of neurons. (Figure 19). 
 
 
Fig. 19: Characterization of D50 DA- enriched neuronal culture. Immunocytochemistry of control SP11#1 
neurons at D50. Representative images of a D50 cuture stained for (A) MAP2 co-expressed with TH, 
dopaminergic specific marker. (B) TH dopaminergic marker with the relative quantification in each 
differentiated line (C), (D) TH and GFAP marker of astrocytes always absent from the culture, (E) TH and 
Calbindin, markers of A10 interneurons, and (F) TH and 5HT marker of serotonergic neurons. 
 
Markers for midbrain DA neurons (FOXA2, GIRK2) and their quantification (Figure 20) 
confirm the commitment of the culture toward a ventral midbrain dopaminergic fate. DAT 
dopamine transporter marker, Synapsin1 marker for synaptic vesicles and PSD95 markers 
for post synaptic vesicle were used to confirm the capability of our neuronal culture to create 
 59 




Fig. 20: Commitment of the DA neurons toward A9. Representative images of a D50 cuture stained for (A) 






Fig.21: Expression of functional proteins in DA neurons. Representative images of D50 culture stained 
for (A) TH and DAT dopamine transportes specific marker of mature dopaminergic neurons and (B) TH, PSD 
95 post-synaptic protein and synapsin, presynaptic protein. 
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We recorded neuronal functional activity at D35, D50 and D80 and saw no degeneration of 
the DA neurons at these stages. To confirm this we quantified the number of dopaminergic 
neurons for each timepoint and saw that between D35 and D50 there was an increase in 
the DA neuron numbers due to the ongoing differentiation process in the culture, while 
between D50 and D80 the number of DA neurons remain unchanged meaning that the 
population was stable and no major neurodegenerative events occurred. The main variability 
between lines was observed at D35, an early stage of differentiation. Here, control and PD1 
lines showed about 10% TH/DAPI positive cells, whereas the rest of the lines showed closer 
to 20%. At D50 and D80, considered late stages of differentiation, all lines showed a similar 
TH/DAPI ratio (between 30-35%). 
The absence of neurodegeneration was crucial for our functional experiments since we 
wanted to assess early functional alterations that happen before the neurodegeneration and 
the selective dopaminergic death.  
Maintaining our neurons in culture for a very long period (D120) we were able to reproduce 
the PD phenotype of specific DA neuron death in the PD lines, confirming the efficacy of the 




Fig.22: DA expression in CTR and PD lines. Representative images of neuronal culture form CTR and PD1 






3. PD DA neurons show synuclein accumulation after culturing without neurotrophic 
factors 
 
Comparing the neurons derived from the two PD lines with the neurons derived from the 
controls, when cultured with neurotrophic factors for 30 days of differentiation, no differences 
were observed in the expression of dopaminergic marker (TH).  
In order to verify the appearance of PD-related phenotypes, at D35 we removed 
neurotrophic factors from the cultures for 15 days, stressing the culture condition. The 
absence of neurotrophic factors reduced the efficiency of dopaminergic neuron 
differentiation in both cultures (control and PD lines), which did not exceed 15% of TH 
positive cells, whilst the cultures with neurotrophic factors confirmed the data obtained in the 
previous experiments (30-35% TH positive cells). At D50, the PD lines cultured without the 
neurotrophic factors showed an accumulation of -syn, which is not present in the neurons 
derived from a control line (Figure 23). 
 
 
Fig. 23: -syn specifically accumulate in PD DA neurons. Representative images of neuronal culture 
form CTR and PD1 lines ad D50 of differentiation cultures with and without factors show how similar 
morphology and protein expression in the 2 lines when cultured with neurotrophic factors. Removing the 




4. Control neurons show oscillatory behavior 
  
We used calcium imaging to monitor spontaneous activity in the neuronal cultures at D35, 
D50 and D80. About 1,000 regions of interest (ROIs) were manually selected and their 
fluorescence time evolution extracted (Fiigure 24 A-B). Sharp increases in the 
fluorescence traces (Figure 24 C), revealed neuronal activations, which were analyzed to 
extract the onset times of action potentials. The raster plots (Figure 25 B-C) illustrate the 
global network dynamics of the cultures. Neurons fired either independently or in 





Fig.24: Diagram of calcium imaging analysis. (A) Live images in bright field and the corresponding Fluo-4 
AM (B) fluorescent signal of differentiated neurons (D50) during calcium imaging, yellow squares identify the 
manually selected ROIs (diameter 10um). (C) Calcium traces of selected neurons (ROIs) neurons confirm 
electrophysiological activity. 
 
To provide a quantification of the network average activity by time, we used the Global 
Network Activity (GNA) measure, defined as the number of neuronal activations in a time 
window of 1 second. Our overall analysis of the GNA showed that all studied cell lines 
exhibited a progressive increase of activity during maturation (Figure 25 A). Control lines 
were characterized by a persistent dynamic in which small sized activations coexisted with 
larger, full network ones. We consider this behavior as “oscillatory behavior” in which the 





Fig. 25: Dynamic characterization of the DA neurons. (A) Average GNA for all experiments at different 
maturation days. Minimum number of independent experiments: n=2. (Coefficients of determination for 
linear regressions: CTR-SP11 R2:0.9238; isoPD1-SP12 wt/wt R2: 0.999; PD1-SP12 R2: 0.4942; PD2-SP13 
R2: 0.6006). (B-C) Raster plot representation of the activity of control cultures at D80. Each plot represents 
2 minutes of recording. Scale bar 1 min.  
 
The GNA analysis demonstrated the first dynamic difference between the control and PD 
lines. 
 
5. PD neurons show hyper activated, hyper synchronous behavior 
 
PD lines displayed a two-state dynamic, completely different to the oscillatory behavior 
used to describe the dynamic of the controls. A two-state dynamic is characterized by 
strong synchronous events combined with quiescent intervals. Since the rate of activity 
increase was similar in all lines (PD and control), we hypothesized that the structure of 
collective activations, and not average individual neuronal activity, was the key feature of 
the malfunctioning behavior. Control and PD neurons show distinctive GNA patterns, 
suggesting the existence of intrinsically different network mechanisms in the two systems, 
resulting in a markedly different collective behavior (Figure 26 A-B). 
To quantify these differences, we analyzed the amplitude of the GNA events and extracted 
those that exceeded one standard deviation from the mean, categorizing them as ‘extreme 
events’. The ratio between these extreme events and all observed events is shown in 
Figure 26 C and the frequency of occurrence of extreme events is shown in Figure. 26 D. 
Data shows that PD lines tend to exhibit stronger and more frequent extreme events than 
control lines. We can conclude that PD lines display an abnormally high synchronous 





Fig. 26: Characterization of the oscillatory mixed mode and hyper synchronous dynamic behavior of 
CTR and PD neuronal culture. Examples of GNA for (A) control (CTR SP11) and (B) Parkinson Disease 
(PD1 SP12) experiments (D80). The orange bars indicate different network bursts amplitudes. The dashed 
grey lines show the dominating dynamics for the two experiments, i.e. low amplitude oscillations for CTR 
and high amplitude bursts for PD1. (C) Ratio of extreme events for all experiments at different maturation 
days (Multiple t-test analysis p-Value: 0.0354). (D) Frequency of extreme events for all experiments at 
different maturation days. (Multiple t-test analysis p-Value D50: 0.01; p-Value D80: 0.0047). 
 
6. Control neurons form a dynamically mature network during the differentiation time 
 
After the dynamic characterization of our lines, our data demonstrates that the global activity 
of controls and PD lines is substantially different. To show that the dynamic differences are 
matched to functional alterations, we studied the neuronal culture behavior in more detail. 
We considered the data at D50 and D80, which corresponds to intermediate and late stages 
of neuronal differentiation. The exclusion of D35 from the analysis is justified by the great 
variability of the culture at this stage of maturation due to the presence of numerous 
progenitors that were not fully differentiated into neurons. 
The analysis was performed using time delays224 to compute the functional connectivity 
among all pairs of active neurons in a given network. A representative functional network for 
the control line is provided in Figure 27 A-B, showing only the top 20% of functional 
connections for clarity. The distribution of functional connections (number of neurons with a 
given connectivity degree, k) averaged over all measurements of the control, is provided in 
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Figure 27 C. The shape of the distribution reflects the topology of the network. A least-
squares fit of the data in log-log scale produced a linear relationship between the 
connectivity degree k and its statistical occurrence. This relationship indicates that there is 
not a characteristic connectivity degree in the network, and that a large number of low-
degree neurons coexist with fewer high-degree neurons.  
Controls display a log-log scaling relationship represented by a straight line. This is a 
fingerprint for scale-free systems, in which interactions among the system’s elements 
coexist at different scales. In the control networks this signifies that neurons participate in 
co-activations of different sizes, from few neurons to the entire network, a behavior that 




Fig. 27: Functional characterization of CTR neuronal networks. (A) Image of Fluo-4 AM fluorescent signal 
from CTR differentiated neurons (D80) with the corresponding extracted functional network (B). (C) 
Distribution of degree, or number of functional connections, for all the control experiments at day 80. In log-
log scale, the probability of a neuron of having a particular degree is linearly correlated with the degree itself, 




7. PD neurons do not create a mature network and show impairment in functionality 
 
Analyzing the functional connectivity traits of the PD lines we see that the least-squares fit 
provides a flat curve with a cut-off at large connectivity degree k (Figure 28). This is 
markedly different from the control lines. This distribution suggests the existence of 
neurons with different connectivity degrees but no logical relation between them. No 
network was created by this system, so the functional activity is much poorer than 
displayed in the control lines. Although there is variability in the connectivity degrees of the 
neurons, the overall distribution is smaller compared to control lines. The richness in 
connectivity and network dynamics, typical of the control, is lost in the PD lines, with 





Fig. 28: Functional characterization of PD neuronal networks (A) Image of Fluo-4 AM fluorescent signal 
from PD1 differentiated neurons (D80) with the corresponding extracted functional network (B). Distribution 
of degrees for all PD1 experiments. In this case, the power-law fit of the distribution does not show a linear 
trend in log-log scale. 
 
8. Control neurons show scale-free functional behavior  
 
A characteristic of scale-free networks is a straight power law relationship between the 
number of connections and the number of hubs (in this case neurons)276,291–293. Scale-free 
distribution in a neuronal network is generally considered an indicator of physiologically 
healthy behavior. The low number of highly connected neurons means that the average 
importance of any given neuron to the network is low. Randomly removing one neuron 
from the network has little to no negative effect on the overall network performance as 
other neurons are able reconstruct the lost connections. 
We examined the connectivity of our iPSC-derived neuronal networks, plotting the data 
against a standard scale-free network model to verify the strength of the networks. We 
compared our results at D50 and D80 against the standard Barabási-Albert model of 
scale-free network behavior to calculate how close they are to ideal scale-free distribution. 
A higher value R2 (Figure 29) indicates a strong correlation between our experimental data 
and the model. The control lines resulted in similar, high R2 values for the two time points 





Fig. 29: Closeness to scale free distribution. Parameter that indicate how similar to scale free distribution 
are the experimental degree distributions both from CTR and PD lines at different timepoints (2 way ANOVA 
analysis, p-Value <0,1). 
 
9. PD neurons show impairment in network functionality 
 
The neuronal networks derived from PD lines show a different behavior, distinct from the 
scale-free distribution that we consider a sign of healthy network functionality. The R2 
values of the PD lines (Figure 29) clearly show the PD1 network concorded with the 
control networks at D50 but dramatically departed from the control lines by D80, signaling 
the onset of functional alterations. The PD2 network has already partially diverged from 
the healthy behavior at D50, a result that hints at a more aggressive progression of 
functional alterations in this line.  
This result strongly suggests that the LRRK2 mutation undermines the development of 
scale-free neuronal networking to such an extent that it disrupts the collective activity and 
functional organization of the circuits. This has a negative impact on the fault tolerance of 
the neuronal network and increases the likelihood of a connectivity failure. 
 
10. Control DA neurons display a normal subpopulation dynamic  
 
To investigate the origin of the functional impairment that we described in PD lines at late 


















lab. We generated a genetic reporter construct that could robustly and reliably label DA 
neurons by using a genome-editing technology to knock-in a P2A-mOrange adjacent to 
the last exon of the TH gene. We chose mOrange because it is one of the brightest 
monomeric fluorescent proteins available295. The designed CRISPR/Cas9 guide RNA 
spacer sequence overlapped the TH gene stop codon, avoiding retargeting of properly 
edited alleles (see methods). At D50 of the differentiation process, cells were live imaged 
(Figure 30 A) and fixed to confirm the fidelity of the reporter. Immunofluorescence analysis 
of the fluorescent neurons revealed an absolute correlation between mOrange signal and 
both TH- and mRFP1- immunoreactivity (mOrange is a mRFP1 derivative) (Figure 30 B). 
Conversely, the MAP2-positive neurons that were negative for TH were also negative for 
mOrange (Figure 30 C), confirming the specificity of the transgene in reproducing the 




Fig. 30: Characterization of DA neurons derived from TH reporter line. (A) Differentiation towards 
floorplate DA neurons gives rise to fluorescent cells (BF mOrange-LIVE imaging). (B) Representative image 
of D50 Dopaminergic neurons co- express TH (green) and mOrange (red) and (C) pan-neuronal MAP2 
(green) and reporter-derived mOrange (red) staining. This confirming the presence of MAP2 positive 
mOrange/TH negative cells. Scale bar: 50um. Number of independent experiments n = 3 
 
The genetic reporter tool allows us to identify TH and non-TH neuronal populations in the 
networks and analyze their functional characteristics separately.  
In Figure 31  we see the 2 neuronal layers, one corresponding to TH neurons (red) and another 
one corresponding to non-TH neurons (blue) (Figure 31 B). An inspection of the activity 
patterns for the control lines reveals that the two subpopulations exhibit different collective 
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dynamics. The non-TH subpopulation is characterized by a persistent activity; whereas the 
TH population shows a two-state dynamic that combines synchronous events with 
quiescent intervals (Figure 32 A).  TH and non-TH activity ratios for the control were 
similar at D50 and D80 (Figure 32 C). To complete the functional analysis, we investigated 
the functional connectivity of the two subpopulations and explored the closeness of the 
inferred distributions to scale-free. The non-TH connectivity degree distribution was highly 
similar to a scale-free network, while the TH distribution departed from it (Figure 32 D). 
These distinct functional traits among populations were maintained through development 
and suggest that the non-TH neurons are responsible for building the scale-free network 
whilst the TH neurons have little impact. 
 
 
Fig. 31: Grafic representation of ROI used to plot functional connection between TH and non TH 
neurons. Analysis of dynamics of TH+ and non TH+ neurons. (A) Image of Fluo-4 AM fluorescent signal 
from CTR differentiated neurons (D80) with the correspondent extracted functional network indicating the 
position of TH+ neurons, in red, and non TH+ neurons, in blue 
 
11. PD TH neurons display abnormal subpopulation dynamic that affects the network 
behavior 
 
As mentioned before, the PD lines display a two-state dynamic. Using the TH-reporter, we 
verified that this dynamic is common to both subpopulations, with a clear abundance of 
extreme events (Figure 32 B). The activity ratio in PD lines switched from TH dominated at 
D50 to non-TH dominated at D80 (Figure 32 C). These results show an abnormal dynamic 
in the subpopulations in PD networks, with a reversal in leadership of TH and non-TH 
subpopulations during differentiation. 
In the PD neuronal network organization, at D50, the TH distribution was the closest to a 
scale-free behavior, while the non-TH departed from it. By D80, both distributions lose 
their similarity to scale-free network behavior (Figure 32 D). These results reveal that 
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network communicability and information flow in PD networks is substantially different to 




Fig. 32: Dynamic characterization of TH and non TH neurons. (A-B) Raster plots of TH+ and non TH+ 
neurons for both CTR-TH (SP11-TH) and PD1-TH (SP12-TH) lines. (C) Ratio of extreme events for each 
subpopulation of neurons at two late maturation days (D50 and D80). (D) Closeness to scale free 
distribution indicating the goodness of fit between experimental degree distributions and a power-law 
distribution generation model (2 way ANOVA analysis, p-Value <0,1) for each subpopulation of neurons at 
two late maturation days (D50 and D80). 
 
 
12. PD TH neurons have short neurites compared to control 
 
To investigate the causes of alteration in the network dynamic and functionality of 
PD neurons we checked a known PD phenotype already described with our model: 
the retraction of the neurites. We tested this hypothesis using an in silico model 
designed by Dr. Malagarriga, under the supervision of Prof. Jordi Soriano. Our 
mathematical simulation reproduces the functional behavior of the control neurons’ 
network. We used experimental data to display the ROIs in the field (Figure 33 A), 
randomly distributing the correct ratio of DA, excitatory and inhibitory neurons 
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(Figure 33 B). With this model, we were able to reproduce the behavior of the control 
neurons, characterized by a strong background activity, or small coordinated 




Fig.33: Numerical in silico simulations of CTR and PD1 lines. (A) Image of Fluo-4 AM fluorescent signal 
from CTR differentiated neurons (D80) used for posterior numerical simulation. (B) Random neuronal 
positions were assigned to excitatory (blue circles), inhibitory (green diamonds) and dopaminergic neurons 
(red hexagons). (C) Random pruning algorithm, through which random connections to the dopaminergic 
subpopulation are removed.  
 
Using our in silico model we simulated the loss of neurites as a reduction of 80% in 
the connectivity probability of the TH population (Figure 33 C). When a minimum of 
10% of the TH neurons are affected the network moves towards on exceedingly 





Fig. 34: Raster plot representing the in silico simulation of CTR and PD conditions. (A) 
Experimental raster plot for a CTR culture at D80 and a simulated counterpart (B). Simulations were fitted to 
experimental data in order to display similar dynamic. (C) Raster plots of each neuronal subtype for 
simulated CTR. (D) Experimental raster plot for a PD1 culture at D80 and its simulated counterpart (E). The 
best matching dynamics for the simulated PD1 culture were obtained after applying a random pruning of a 
80% of connections onto a 10% of the dopaminergic subpopulation. (F) Raster plots of each neuronal 
subtype for simulated PD1. 
 
To confirm this hypothesis in our biological culture, we examined neurite density in the 
control and PD neurons at D50 and D80.  We observed a much lower number of TH 
neurites in the PD lines. The deficit was already present at D50 and accentuated at D80 
(Figure 35 A). This result was consistent among all the experimental instances.  
Additionally, the number of neurites increased in the DA control populations during 
development while it decreased in PD lines, indicating a progressive worsening of network 
structure for the latter (Figure 35 B). We also analyzed the number of neurites in MAP2+ 
neurons in both lines and no significant differences were observed (Figure 35 C). Taken 
together, these results prove that the dynamic and functional deficits of PD lines are 
localized in the TH subpopulation, and that these cells experience a gradual structural 





Fig. 35: Neurite quantification to corroborate the data of the in silico model. (A) CTR (SP11) and PD1 
(SP12) TH+ neurons are tracked to determine the number and the structure of the neurite at D50 and D80 
(scale bar: 50um). (B) The quantification of the number of TH neurites shows significant differences 
between CTR and PD1 both at D50 and D80 while no difference were found when analyzing MAP2+/TH- 
neurons (C). Multiple t test analisis p-Value D50 (<0.01*104) and D80 (<0.01*103). Number of independent 
experiments n = 3. 
 
13. Gene expression profile analysis reveals little difference in biological and molecular 
pathways 
 
Our experiments have demonstrated that in PD DA neurons higher synchronicity leads to 
a general alteration of the network. Using the biophysical model developed in collaboration 
with Dr. Malagarriga, we simulated the experimental alteration and verified that a known 
feature of LRRK2G2019S DA neurons, neurite arborization, was a cause of the functional 
alteration that we were able to describe in our PD in vitro culture. 
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We then used our in vitro model to take a step backwards and examine the biological and 
molecular behavior before the functional alteration manifests. We analyzed the culture at 
D50, when the data suggests that the functional alteration has not yet developed fully, 
using gene expression profile analysis to identify possible deregulations in pathways that 
can be connected to the altered functionality. 
To address this question, we generated 3 independent biological replicates of ventral 
midbrain DA neurons from 5 different lines: 1 control, 2 PD lines (PD1 and PD2) and the 
relative 2 corrected isogenic lines. At D50 we harvested the cells and performed RNA 
extraction. The RNA obtained was then processed by nanoString machine in order to 
individuate the gene expression profile of each line using a commercial gene panel related 
to neuropathology. We analyzed the raw data using ROSALIND bioinformatics296 
developed by OnRamp BioInformatics, Inc. (San Diego, CA). 
The ROSALIND program revealed that our iPSC-derived neurons do not show more than 
1.5-2% difference in the genomic expression profile of each line (Figure 36 A). Our 
analysis focused on differentially expressed genes, selected with a pAdjValue of 0.05 and 
a fold change -2 and  2. Within these strict selection criteria, we were unable to highlight 
any gene related to LRRK2 PD and isogenic PD (Figure 36 B). This confirms the validity of 
the in vitro model and the robustness of the differentiation protocol and shows that the 
functional phenotype is not due to macroscopic neurodegenerative conditions. 
Future investigation could relax the strict selection criteria and examine small, specific 
changes in the gene expression which can be connected to the functional alterations. 
Small deregulations in these pathways could be used for drug screening and as early 
biomarkers to identify the disease.  
 
 
Fig.36. Gene expression profile analysis of D50 DA neurons. A. Principal component analysis describe a 
1.5-2% difference in the genomic expression profile of each line. B. Gene expression heatmap show little 
difference between CTR, PD and isogenic D50 DA neurons confirming the robustness of our in vitro protocol. 
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14. Isogenic PD LRRK2G2019S show an overall less active dynamic but a full recovery in 
functional behavior and neurite length 
 
Using isogenic lines is important for our investigation as it gives us insight into the 
penetrance of the mutation and its direct involvement in the different aspects of the disease’s 
pathogenesis. We know from the literature that the LRRK2G2019S mutation has a 
pathogenesis indistinguishable from idiopathic forms of PD. Molecularly this mutation is 
mostly associated with common PD cellular phenotypes such as autophagy dysfunctions, 
signaling impairment and mitochondrial pathological phenotypes. In our cell model, the 
isogenic PD lines were able to recover from the phenotypes that we described in the PD 
lines. Isogenic PD lines partially recovered their dynamic activity. They show a consistent 
progression in neuronal calcium activity during the 3 different time points analyzed but they 
never reach the level of activation of the control or PD lines (Figure 24 A). The isogenic 
neurons show an oscillatory behavior typical of the control lines and noticeably different from 
the hyper active, hyper-synchronous behavior of the PD lines (Figure 25 B-C). The functional 
behavior of the isogenic neurons was similar to the control lines and displayed a high 
closeness to scale-free behavior (Figure 29). The isogenic PD DA neurons fully recover their 
neurite length, similar to the control DA neurons and never show neurodegeneration typical 






For this study, we have efficiently differentiated 6 iPSC lines into DA neurons and 
monitored their functional activity using calcium imaging assay. The first step of production 
of the correct type of neurons is not trivial. iPSC technology offers us a great opportunity to 
investigate systemic and complex diseases, especially neurological diseases. With 
previous methods it was very difficult to directly study the molecular mechanisms and 
pathophysiological stages of the disease, but we are now able to derive specific neuronal 
cell types directly from patients.  
For studying PD, it is important to generate A9 ventral midbrain DA neurons. This specific 
cell type gives us the confidence that the phenotypes we are observing and describing are 
directly and accurately connected with the disease and not an artifact of the in vitro model. 
(FIND PAPERS). Our differentiation process resulted in ~35% A9 ventral midbrain DA 
neurons which gives us confidence that we are reproducing consistent and robust data, 
describing the first phases of the pathophysiology of PD.  
We have confidence in the model because: 
Our iPSC lines were already used to demonstrate PD related phenotypes and we 
reproduced and validated this; 
Our cultures consistently express DA-specific progenitors and mature DA-specific 
markers; 
We used a reporter line that allows us to identify DA neurons (TH+) and differentiate them 
from the non DA neurons (TH-). 
Having validated our neuronal culture, we carried out in-depth functional analysis using 
calcium imaging to identify early signs that can be used to predict morphological 
neurodegeneration and death of the DA specific neurons.  
 
All of our neuronal cultures were active and displayed calcium spikes during the different 
analysis time points. Each line grows their overall activity from D35 to D80 and we notice 
an evolution in the dynamic of each line. Focusing on the intrinsic characteristics of the 
dynamic activity of the neuronal cultures, we were able to identify two distinct patterns of 
activity: controls lines display a mixed mode, oscillatory activity while PD lines display a 
two-state dynamic, characterized by hyper-active and hyper-synchronous behavior, with 
strong bursting events combined with intervals of almost no activity. 
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Based on this observed behavior, we carried out functional network analysis and 
demonstrated that: 
Mixed mode, oscillatory behavior is related to a scale-free distribution of the neuronal 
network, and correlates with healthy functional connections between the neurons; 
The ‘all-or-none’ hyper-active hyper-synchronous behavior of the diseased neurons 
diverges from a scale-free distribution of the neuronal network and is a sign of altered 
functional connectivity between neurons. 
 
Using genetic TH reporter lines, we were able to focus on just the DA population of our 
neuronal culture. Our analysis shows that, in healthy conditions, DA neurons never 
overrule the non-DA neurons in organizing the network behavior, they remain integrated 
and function in line with the general network activity. 
PD DA neurons, on the contrary, already dictate the neuronal network activity at the first 
stage of functional analysis (D50), spreading the hyper-synchronous dynamic to the non-
DA neurons and altering the network by D80. 
These data are sustained by the literature which describes an increase in a “strongly 
interconnected between-network” state in PD patients. This means that PD patients, like 
our in vitro PD neuronal networks, lose the capability of creating long distance, modulated 
and organized oscillatory connections and diverge into a hyper-active hyper-connected 
state. This state suggests a lack of regulation, with the network missing the physiological 
crosstalk and modulation that normally organize the neuronal connections. The PD 
neuronal network dynamic has  a clear fingerprint that can be use as guidance to develop 
early diagnostic tests. We demonstrated that this dynamic is connected with the loss of 
neurite arborization, a known PD phenotype, confirming the authenticity of the model. We 
were also able to identify a potential therapeutic window during which some of the neurons 
are functionally affected but no neuronal loss has occurred and morphological 
neurodegeneration is not happening. 
The next challenge is to translate these in vitro data into clinical applications.  
More in-depth characterization of the model and its applicability to biomarker discovery 
and drug screening could follow 2 different approaches: 
Organoids and 3D complex cultures 
As mentioned before cellular neuroscience mainly rely on in vitro animal models297, ex vivo 
brain slices298 and in vitro 2D cultures. These different experimental conditions show 
limitations in understanding the complexity of the biology, chemist and physic underlying 
the basic processes that happen in the brain. In vivo animal model cannot reproduce the 
human cognitive abilities at the cellular level and fail into reproduce human relevant data 
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and clinical features299. Brain slices are too sensitive to axotomy and this limitation creates 
artifacts and variability inducing neuronal death300,301. 2D in vitro culture allow the 
investigation of basic cellular and functional neuronal network data but lack the in vivo 
complexity and microenvironment, do not resemble the architecture typical of a 3D 
complex system302.  
3D brain organoids, new tissue engineering technology derived from stem cells, are able 
to overcome the previously described limitation and offer new opportunities in brain 
modeling303–305.3D brain organoids have already been used to model early-onset 
neurologic disease variants such as early-onset AD306. 3D brain organoids derived from 
early-onset familial AD (fAD) patients showed AD phenotypes including β-amyloid 
aggregation, hyper-phosphorylated Tau (pTau), and endosome abnormalities307. These 
data suggest that brain organoids have the great potential to expand our knowledge of 
physiological and pathological features, not just for neurodevelopmental diseases but also 
for the neurodegenerative ones. They may allow higher order investigation of mechanisms 
and functionality and their 3D nature means that they can also give new insights into cell-
to-cell interaction, modelling distinct brain regions and their specific connections. 3D-iPSC-
based brain organoid models enable researchers to analyze molecular and 
pharmacological effects in a complex tissue system, functioning as a drug screening 
platform. We can go further using the great efficiency of the current protocols to generate 
organoids that can be used as a personalized medicine tool if iPSC are derived from 
specific patients. Furthermore, 3D-cultured organoids remain viable for much longer than 
2D-cultured neurons, as long as nutrients and oxygen are sufficiently supplied. Therefore, 
the 3D culture system provides an exciting platform for exploring pathogenesis caused by 
long-term neurotoxicant exposure and chronic cellular response.  
The interaction between non-neuronal cell populations and neuronal function has become 
one of the most useful features that can be modeled by 3D brain organoids.  More efficient 
culture techniques that increase the complexity of the neural and non-neural population 
are under study, coupled with imaging and functional assay that are needed to ameliorate 
this potentially powerful tool. To date the main limitation of brain organoids is that most 
neurodegenerative diseases manifest at a late developmental stage and the lack of 
vasculature structures in organoids may prevent them from developing full 
physiological/pathological maturation. Vascularization is essential for neuronal progenitor 
differentiation in the subventricular zone during late development308. This limits PD 
modelling because degeneration of nigrostriatal projection neurons is the primary cause of 
PD symptoms, and vascularization is an essential first step to begin the enormous task of 
modelling a functional nigrostriatal circuit in a culture setting. Techniques have been 
developed to address the lack of vascularization such as building a vascular 
microenvironment with microfluidic chambers, further mimicking the physiological niche 
that promotes neurogenesis309–311. In the tissue scaffold created by the microfluidic 
chambers, pre-capillary networks were built by co-culture of pericytes and early vascular 
cells derived from iPSCs312,313. This approach was able to facilitate the generation of 
physiologically relevant vascular networks for neurogenesis. Using a combination of these 
new techniques, perfusion-based human iPSC-derived 3D brain organoid platforms can 
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make our in vitro model even more realistic and effective in understanding the 
pathophysiology underlying neurodegenerative diseases. 
Artificial Intelligence 
Artificial intelligence (AI) techniques can be applied in translational and wide approaches 
for the study of neurodegenerative disorders. 
The main characteristic of AI techniques that make them suitable to biological research 
and development is their efficiency in handling large data sets. Pairing AI techniques such 
as deep learning with mathematical in silico models allows us to produce and analyze vast 
numbers of scenarios, working out which parts are statistically relevant and might be 
applied in the biomedical field without needing to experimentally test all possible 
combinations.  
AI is already being applied in diagnostic processes, making them faster and less 
susceptible to errors. AI can recognize common patterns in fMRI, DAT or PET brain scan 
datasets allowing for a much faster identification of anomalies than traditional methods314. 
We can use AI to help with the identification of potential drugs and biological targets that 
would lead to better treatments. AI can be used to analyze and disassemble the functional 
behavior of each drug molecule, allowing us to re-purpose them into new treatments for 
other type of diseases and reexamine previously failed molecules that may have more 
success in different therapeutic areas. 
The application of AI to personalized medicine can create a new form of healthcare based 
on personal genetic and physiological conditions. Personalized drug molecules, able to 
deliver targeted therapies that are tailored to each patient can be designed. This will help 
us to better understand the basic molecular cause of neurodegenerative processes, 







• Ventral midbrain dopaminergic neurons (DAn) were efficiently generated from 
induced pluripotent stem cells (iPSC) representing healthy individuals (Ctrl) and 
LRRK2 associated PD patients. 
 
• LRRK2 PD and Ctrl DAn formed complex networks that showed evident signs of 
functional maturation over time. 
 
• PD neuronal networks developed a dynamically abnormal hypersynchrony, in 
contrast with healthy or gene-edited isogenic PD networks that presented an 
oscillatory-mixed mode. 
 
• The functional connectivity of the controls displays a log-log scaling relationship 
represented by a straight line. This is a fingerprint for scale-free systems, in which 
interactions among the system’s elements coexist at different scales. In the control 
networks this signifies that neurons participate in co-activations of different sizes, 
from few neurons to the entire network, a behavior that concords with the low ratio 
of extreme events observed. 
 
• On the contrary the functional connectivity traits of the PD lines using the least-
squares fit shows a flat curve with a cut-off at large connectivity degree. This 
distribution suggests the existence of neurons with different connectivity degrees 
but no logical relation between them. No network was created by this system, so 
the functional activity is much poorer than displayed in the control lines. 
 
• Using dopaminergic neuron lineage tracing we demonstrate that in the control the 
non-TH neurons are responsible for building the scale-free network whilst the TH 
neurons have little impact. 
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• Analyzing the behavior of TH and non-TH neurons in the PD lines we see an 
abnormal dynamic in the subpopulations of PD networks, with a reversal in 
leadership of TH and non-TH subpopulations during differentiation. These results 
reveal that network communicability and information flow in PD networks is 
substantially different to our controls, and that this affects both TH and non-TH 
neurons throughout differentiation. 
 
• The generation of an in silico model based on our experimental data suggests that 
one of the primary causes of the functional alteration is the random pruning of TH 
neurites. To confirm this hypothesis in our biological culture, we examined neurite 
density in the control and PD neurons at D50 and D80. We observed a much lower 
number of TH neurites in the PD lines. The deficit was already present at D50 and 
accentuated at D80 while the number of neurites in MAP2+/TH- neurons showed 
no significant differences. 
 
 
• Gene expression profile analysis revealed that our iPSC-derived neurons do not 
show more than 1.5-2% difference in the genomic expression profile of each line 
suggesting no clear difference in the gene expression between controls, LRRK2 
PD and isogenic PD. This confirms the validity of the in vitro model and the 
robustness of the differentiation protocol and shows that the functional phenotype 
is not due to macroscopic neurodegenerative conditions. 
 
• Thus, our results identify early alterations in PD neuronal function that predate the 
onset of neuron degeneration and highlight the extraordinary window of opportunity 
that iPSC-based experimental models provide into pre-symptomatic assessment of 
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1. Techniques applied in other projects 
1.1. HEK 293T 
 
HEK 293T line were used to produce lentivirus. 1 million cells were thawed in a 10 cm dish using 
10% FBS DMEM with 1% Pen/Strep and passed the next day 1:4. After reaching confluence 
(approx. 48h later), each 10 cm dish was passed in a 15 cm dish. Each virus production request 7 of 
the 150mm dish.  
 
1.2. Kit Invitrogen  
 
Next, we differentiate our iPSC in ventral midbrain dopaminergic neurons with a commercial 
kit from Thermo Fisher (CITE) that allows the expansion and storage of dopaminergic 
precursors.  
This characteristic was tested in the previous 2 protocols but we notice that the precursors 
during the period of expansion and storage loose part of the dopaminergic differentiation 
potential while in this protocol the differentiation potential was descripted to be stable for 10 




Fig 9. Schematic representation of the commercial protocol that we used to differentiate ventral midbrain 
specific DA NPCs 
 
During the first step we maintain the cells in matrigel with conditioned HES medium and 
Specification medium. We tested again at different time (7, 9, 10, 11, 15) points the co- 
expression of FoxA2 and Lmx1A. The commercial protocol suggest DIV10 as the best timing 





Fig 10. Schematic representation of the expansion step of the commercial protocol that allow us to store 
ventral midbrain DA progenitors. 
 
When the cells reach confluence, we split them first on laminin and then maintain them in 
suspension to expand them and freeze them for banking.  
At this stage our precursor was stored at passage 2 and they were able to be thawed and 
differentiate in ventral midbrain dopaminergic neurons. 
 




Fig 12. Scheme describing the recombination steps during the edition process. Green arrows represent the 




We edited the synuclein locus with FLAG-TAG in CTR (SP11#1) and PD1 (SP12#3) lines 
using the CRISPR/Cas9 gene editing method. Complementary oligos encoding for the 
desired spacer sequences were annealed into the BbsI site of the gRNA scaffold of the 
Cas9-T2A-EGFP/gRNA co-expression plasmid px458 (Addgene, #48138). A full-length 
version of the CAGGS promoter was used to improve the expression in iPSC. The cleavage 
efficiency of two gRNAs was tested by T7EI assay. Both gRNAs displayed a similar cutting 
efficiency but gRNA2-OL was selected for the editing process. Donor plasmid for knocking-
in a FLAG tag fused C-terminal to the α-synuclein open reading frame (ORF) was 
engineered using two homology arms (HAs) spanning approximately 800 bp from both sides 
of the STOP codon. The sequence encoding for the FLAG tag was placed immediately after 
the last codon of the SNCA ORF and before the STOP codon. A selection cassette (pRex1-
NeoR) surrounded by loxP sites was cloned between the STOP codon and the 3’HA. 
The clone, characterized by sequence, immunofluorescence and WB, was successfully 
edited and karyotypically normal. 
Next we plate 800.000 iPSC in a 10cm dish with matrigel, the next day they were 
cotransfected with a mix of 6 µg of Cas9-T2A-EGFP/gRNA, 9 µg of the donor plasmid, 45 
µL of FuGENE HD (Promega) transfection reagent, and KO-DMEM up to 750 µL. The mix 
was incubated for 15min at room temperature and added drop by drop in the culture dish. 
72h later G-418 (50 µg/mL) selection was applied and the emerging colonies were selected 
and each one was transferred in a single well. The colonies that, by PCR, display the correct 
insertion were screened and then transfected with CRE-recombinase expressing plasmid. 
After that the cells were disaggregated to single cell and re-plated on top of human irradiated 
fibroblast feeder layer in presence of Rock inhibitor (Miltenyi). After the second screening 





Fig 13. WB on SP11#1 SNCAflag and SP12#3 SNCAflag positive clones after 3 weeks of neuronal 
differentiation on PA6. Positive control is done using protein extraction from 293T transfected with plasmid 
expressing flag. Negative control is iPSC not transfected.  
 





SP11#1_#2 neuron differentiation SP12#3_#3 astrocyte differentiation 
  
Fig 14. Immunofluorescent colocalization analysis of flag and alpha-synuclein in neurons from CTR (SP11#1 




1.4. Set up the co-culture system 
 
DIV 35 immature/young neurons were used to set up and investigate the process of 
differentiation and maturation of neurons on top of iPSC derived astrocytes. 1 week before 
plating the neurons, 20.000 astrocytes were plated on the top of matrigel coated glass cover 
slides in 24-well plates to ensure their full development and to provide sufficient co-culturing 
time before the cells would be affected by prolonged placement in the culture. vmDAn from 
a LRRK2-PD line were generated and 5x104 cells/well were plated on the top of one-week-
old astrocytes and left it for two and four weeks. The medium used contained Neurobasal, 
2%B27, 1% NEAA, 1%PenStrep, and 1% Glutamax and half of it was changed twice a week. 
Cells were fixed with 4% PFA for 15 mins and washed three times with PBS for 15 minutes 
before performing ICC. After confocal images were acquired, TH positive cells and DAPI 








Fig 16. Schematic representation of the differentiation protocol from the commercial kit that were used to 
generate DA neurons 
Following the kit instruction vmDA neurons were generated from the frozen precursors 
obtained with the kit. These sphere were thawed in commercial expansion medium 
supplemented with Rock inhibitor and after 3 days disaggregated and plated on top of 24 
well plated cover glasses coated with Poly-D-Lysine) 100 μg/mL and Laminin (1 µg/mL). 
The disaggregation process start washing the spheres twice with PBS, then move them in 
a 15ml falcon and add 0,5ml of Accutase (eBiosciences), incubate the sphere for 10 min at 
37C. Next with the 200μl tip homogenize the spheres in smaller pieces and centrifuge them 
800rpm for 5min. Re-suspend the cells in 1ml of expansion medium with Rock inhibitor and 
count them. Plate 1x105 cells in each well. Fix the culture after 15 and 30 days (DIV30 and 
50) with PFA4% and check the neural differentiation with TH, MAP2, FoxA2, DAT and Girk2. 
 
1.6. Protein extraction 
 
Live cells were washed twice with PBS, lifted with a scraper and collected DPBS. The 
samples were centrifuged at 800rpm for five minutes. After centrifugation, cells were re-
suspended in cold PBS and placed in 1.5mL eppendorfs and centrifuged for five minutes at 
4ºC at 600xg. Discart the supernatant and store the pellet at -80ºC. For extracting the 
proteins pellets were homogenized in 50 mM Tris-HCl, pH 7.4/150 mM NaCl/0.5% Triton X-
100/0.5% Nonidet P-40 and a mixture of proteinase inhibitors (Sigma, Roche tablet). 
Samples were then centrifuged at 15,000xg for 20 minutes at 4ºC. The resulting supernatant 
was normalized for protein using BCA kit (Pierce). 
Protein extraction for oligomeric α-synuclein:  
Mila lysis buffer (0.5M Tris at pH 7.4 contains 0.5 methylenediaminetetra acetic acid at pH 
8.0, 5M NaCl, 0.5% Na doxicholic, 0.5% Nonidet P-40, 1mM phenylmethylsulfonyl fluoride, 
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distilled water, protease and phosphatase inhibitor cocktails) (Roche Molecular Systems, 
Pleasanton, CA, USA), and then homogenized pellet with Mila buffer are centrifuged for 15 
min at 13,000rpm at 4°C (Ultracentrifuge Beckman with 70Ti rotor, CA, USA). 




Cell extracts were then boiled at 100ºC for 5 minutes, followed by 7-15% electrophoresis in 
Running buffer, then electro transferred in Transfer buffer at 100v to PVDF membranes for 
1.5 hours at 4ºC. After treating the membranes with Ponceau S solution (Sigma) in order to 
cut separately the protein of interest and the loading control protein for separated antibody 
incubations, the membranes were then blocked in blocking solution for 1 hour and incubated 
overnight in containing primary antibodies. After incubation with peroxidase-tagged 
secondary antibodies (dilution 1:10,000), membranes were revealed with ECL-plus 
chemiluminescence Western blot kit (Amershan-Pharmacia Biotech). 
 
1.8. Virus production 
 
NaCl 281mM (16,42g/liter), Hepes 100mM (23,83g/liter), Na2HPO4 1,5mM (10 ml of a 
150mM stock solution of 21,29g/liter) were diluted in 1 liter of H2O sigma (W3500) to obtain 
HBS2x, necessary for lenti-virus home-made production. 
Crucial for the protocol is the pH of the HBS2x, so for regulating the pH NaOH 2M (4g in 
50ml) was freshly prepared dissolving the pellets little by little in 35ml of sterile water and 
then reach the 50 ml.  
When the HBS2x solution reach the correct pH (7.09/7.10/7.12) leave it to stabilize 1h 
checking the pH every 15 minute and adjust it if change. 
Filter the solution and store it in aliquots at - 20C. 
The second solution necessary for lentivirus production is CaCl2 2,5M (367,55g/liter). Aliquot 
were stored at -20ºC (exothermic reaction, will not freeze at -20ºC) 
293T are used to produce lentivirus. Seed and incubate cells in a 15 cm dish: 
18 x 106 cells, approximately 8 hours before transfection in 22 ml final volume. 
9 x 106 cells, approximately 24 hours before transfection in 20 ml final volume. 
It’s very important to not let the cells overgrow. 
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Change medium 2 hours before transfection with IMDM, 10% (heat inactivated) FBS, 
Penicillin (100U/ml), Streptomycin (100U/ml) and Glutamine (22 ml final volume). 
For each dish prepare the following DNA mix: 
7 μg of ENV plasmid (VSV-G) 
12.5μg of PACKAGING plasmid, pMDLg/pRRE (III Gen.Pack) 
6.25μg of REV plasmid 
25μg or 32μg of TRANSFER VECTOR plasmid depending on the length of the transgene 
and promoter (1500bp or 3000 bp) 
N.B never use more than 40μg. The plasmid solution is made up to a final volume of 1125μl 
(2250 μl) with 0.1X TE/dH2O (2:1). Finally, 125μl (250 μl) of 2.5M CaCl2 is added.  Leave 
the mix at RT for 5’. The precipitate is formed by dropwise addition of 1250μl (2500 μl) of 2X 
HBS solution to the 1250μl DNA-TE-CaCl2 mixture from step 3 while vortexing at full speed. 
The precipitate should be added to the 293T cells immediately following the addition of the 
2x HBS. High magnification microscopy of the cells should reveal a very small granular 
precipitate of the CaPi-precipitated plasmid DNA, initially above the cell monolayer, and after 
incubation in the 37°C incubator overnight, on the bottom of the plate in the large spaces 
between the cells. 
The CaPi-precipitated plasmid DNA should be allowed to stay on the cells for 12 -14 hours, 
after which the media should be replaced with 1uM Na butyrate containing fresh media (16-
18 ml per dish) for virus collection to begin. 
Collect the cell supernatants at 30 hours after changing the media. 
Ultracentrifuge at 19600 rpm for 2 hours and 20’ in the SW28 rotor. 
Re-suspend the pellet in PBS and concentrate again in SW55 rotor-23000 rpm, 2 hours and 
20’. Aliquot the virus and store it at -80C. 
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3. CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live 
imaging and isolation of dopaminergic neurons 
